Patent Grant
12042208
The embodiments described herein relate generally to medical devices for therapeutic electrical energy delivery, and more particularly to a surgical clamp device for delivering electrical energy to ablate tissue.
In the past two decades, the technique of electroporation has advanced from the laboratory to clinical applications, while the effects of brief pulses of high voltages and large electric fields on tissue has been investigated for the past forty years or more. Application of brief, high DC voltages to tissue, thereby generating locally high electric fields typically in the range of hundreds of Volts/centimeter, can disrupt cell membranes by generating pores in the cell membrane. While the precise mechanism of this electrically-driven pore generation (or electroporation) is not well understood, it is thought that the application of relatively large electric fields generates instabilities in the lipid bilayers in cell membranes, causing the occurrence of a distribution of local gaps or pores in the membrane. If the applied electric field at the membrane is larger than a threshold value, the electroporation is irreversible and the pores remain open, permitting exchange of material across the membrane and leading to necrosis and/or apoptosis (cell death). Subsequently the tissue heals in a natural process. While pulsed DC voltages are known to drive electroporation under the right circumstances, known approaches do not provide for ease of navigation, placement and therapy delivery from one or more devices and for safe energy delivery, especially in the context of ablation therapy for cardiac arrhythmias with epicardial catheter devices.
Thus, there is a need for devices that can effectively deliver electroporation ablation therapy selectively to tissue in regions of interest while minimizing damage to healthy tissue. In particular, there is a need for devices that can efficiently deliver electroporation therapy to desired tissue regions while at the same time minimizing the occurrence of irreversible electroporation in undesired tissue regions.
Described here are systems, devices, and methods for ablating tissue through irreversible electroporation. Such electroporation delivery systems, devices, and methods can enhance safety of energy delivery and broaden the areas of clinical application of electroporation including therapeutic treatment of a variety of cardiac arrhythmias. In some embodiments, an apparatus may include a first jaw including a plurality of first electrodes. A second jaw may include a plurality of second electrodes. The first jaw and the second jaw may be substantially rigid, elongate, and may collectively define a longitudinal axis. The first jaw and the second jaw may be further configured to engage tissue therebetween during use. Each electrode of the plurality of first electrodes may have a width orthogonal to the longitudinal axis that is less than a length of that electrode measured parallel to the longitudinal axis. The plurality of first electrodes may be spaced apart laterally with respect to the longitudinal axis. Each electrode of the plurality of second electrodes may have a width orthogonal to the longitudinal axis that is less than a length of that electrode measured parallel to the longitudinal axis. The plurality of second electrodes may be spaced apart laterally with respect to the longitudinal axis. Each electrode of the plurality of first electrodes and the plurality of second electrodes may be configured to deliver a pulse waveform of at least about 200 Volts.
In some embodiments, an apparatus includes a first jaw including a plurality of first electrodes; and a second jaw including a plurality of second electrodes, the first jaw and the second jaw being substantially rigid, elongate, and collectively defining a longitudinal axis, the first jaw and the second jaw further configured to engage tissue therebetween during use. Each electrode of the plurality of first electrodes can have, within a cross-section of the first jaw and the second jaw that is orthogonal to the longitudinal axis, a width that is less than a length of that electrode, the plurality of first electrodes spaced apart laterally with respect to the longitudinal axis. Each electrode of the plurality of second electrodes can have, within the cross-section orthogonal to the longitudinal axis, a width that is less than a length of that electrode, the plurality of second electrodes spaced apart laterally with respect to the longitudinal axis. The plurality of first electrodes and the plurality of second electrodes can include electrode pairs or sets of electrodes configured to deliver ablative energy to the tissue in response to receiving a pulse waveform having an amplitude of at least about 200 Volts, at least one electrode pair or set of electrodes including an electrode of the plurality of first electrodes and an electrode of the plurality of second electrodes disposed diagonally across from one another within the cross-section orthogonal to the longitudinal axis.
In some embodiments, each electrode of the plurality of first electrodes and the plurality of second electrodes may be independently addressable. In some embodiments, the longitudinal axis has one or more of a straight portion and curved portion. In some embodiments, an electrode of the plurality of first electrodes may be configured as an anode and an electrode from the plurality of second electrodes may be configured as a cathode, the anode being disposed directly across from the cathode. In some embodiments, an electrode from the plurality of first electrodes may be configured as an anode and another electrode from the plurality of first electrodes is configured as a cathode. The anode may be spaced apart laterally from the cathode. In some embodiments, at least two of the plurality of first electrodes may be spaced apart by a first measure. The first jaw and the second jaw may be spaced apart by a second measure, e.g., when engaged with tissue therebetween during use. A ratio of the second measure to the first measure may be between about 0.1:1 and about 12:1. In some embodiments, a distance between a midpoint of at least two of the plurality of first electrodes in a cross-section orthogonal to the longitudinal axis may be between about 1 mm and about 10 mm.
In some embodiments, any two adjacent electrodes of the plurality of first electrodes may be spaced apart by a first measure of between about 0.5 mm and about 10 mm and any two adjacent electrodes of the plurality of second electrodes may be spaced apart by a second measure of between about 0.5 mm and about 10 mm. In some embodiments, any two adjacent electrodes of the plurality of first electrodes may be spaced apart by a first measure and any two adjacent electrodes of the plurality of second electrodes are spaced apart by a second measure. A ratio of the first measure to the second measure may be between about 0.05:1 and about 20:1.
In some embodiments, any two adjacent electrodes of the plurality of first electrodes may be spaced apart by a first measure and any two adjacent electrodes of the plurality of second electrodes may be spaced apart by a second measure. A ratio of the width of any electrode of the plurality of first electrodes to the width of any electrode of the plurality of second electrodes to the first measure may be between about 0.01:1 and about 10:1. In some embodiments, each electrode of the plurality of first electrodes and the plurality of second electrodes may have a length of between about 10 mm and about 120 mm.
In some embodiments, the first and second jaws may be configured to transition between a first configuration for positioning the first and second jaws through or around a body cavity, organ system, or anatomical structure and a second configuration for engaging the tissue. In some embodiments, the first and second jaws may be spaced apart by a spacing distance in the second configuration. In some embodiments, the cross-section (or cross-sectional shape) of each electrode of the plurality of first electrodes and the plurality of second electrodes may be substantially rectangular. In some embodiments, each electrode of the plurality of first electrodes and the plurality of second electrodes may include a curved portion. In some of these embodiments, the curved portion may have a radius of curvature of about 1 cm or larger. In some embodiments, the curved portion may have a J shape.
In some embodiments, each electrode of the plurality of first electrodes and the plurality of second electrodes may include an exposed portion in electrical contact with the tissue during use. In some of these embodiments, the exposed portion of each electrode of the plurality of first electrodes and the plurality of second electrodes may be flat or convex. In some embodiments, the first and second jaws may be parallel, e.g., extend in parallel to one another. In some embodiments, a pulse generator may include a generator. The generator may be coupled to each electrode of the plurality of first electrodes and the plurality of second electrodes. The controller may include a processor and memory. The generator may be configured to generate a pulse waveform of at least about 200 Volts. A first set of electrodes of the plurality of first electrodes and the plurality of second electrodes may be configured for pulse waveform delivery. In some embodiments, the pulse waveform may be delivered to the first set of electrodes. In some of these embodiments, the generator may be further configured to configure a second set of electrodes of the plurality of first electrodes and the plurality of second electrodes for receiving electrical activity of tissue, and receive signal data corresponding to electrical activity of the tissue using the second set of electrodes. Electrocardiography data may be generated using the signal data.
In some embodiments, a handle may be coupled to the first jaw and the second jaw. In some of these embodiments, the handle may include one or more of a jaw control, electrode selection control, and pulse waveform control. In some embodiments, a pivot may couple the first jaw to the second jaw. In some embodiments, a spring may be configured to bias the first and second jaws closed. In some embodiments, one or more lead wires may be coupled to the plurality of first electrodes and the plurality of second electrodes.
In some embodiments, an apparatus may include a first jaw including a first electrode and a second electrode. A second jaw may include a third electrode and a fourth electrode. The first jaw and the second jaw may be substantially rigid, elongate, and collectively define a longitudinal axis. The first jaw and the second jaw may be further configured to engage tissue therebetween during use. The first electrode may be disposed directly across the third electrode. The second electrode may be disposed directly across the fourth electrode. A processor may be operably coupled to the first jaw and the second jaw. The processor may be configured to, during use, configure the first electrode as an anode and the third electrode as a cathode. Pulsed electric field ablative energy may be delivered via the first electrode and the third electrode.
In some embodiments, each of the first electrode, second electrode, third electrode, and fourth electrode are independently addressable. In some embodiments, the longitudinal axis may have one or more of a straight portion and a curved portion. In some embodiments, the first electrode and the second electrode may be spaced apart by a first measure of between about 0.5 mm and about 10 mm, and the third electrode and the fourth electrode may be spaced apart by a second measure of between about 0.5 mm and about 10 mm. In some embodiments, the first electrode and the second electrode may be spaced apart by a first measure and the third electrode and the fourth electrode may be spaced apart by a second measure. A ratio of the first measure to the second measure may be between about 0.05:1 and about 20:1. In some embodiments, the first electrode and the second electrode may be spaced apart by a first measure. A ratio of a width of the first electrode to the first measure may be between about 0.01:1 and about 10:1. In some embodiments, the first, second, third, and fourth electrode may each have a length of between about 10 mm and about 120 mm.
In some embodiments, the first and second jaws may be configured to transition between a first configuration for positioning the first and second jaws through or around a body cavity, organ system, or anatomical structure and a second configuration for engaging the tissue. In some of these embodiments, the first and second jaws may be spaced apart by a spacing distance in the second configuration. In some embodiments, the cross-section of the first, second, third, and fourth electrodes may be substantially rectangular. In some embodiments, the first, second, third, and fourth electrodes may include a curved portion.
In some of these embodiments, the curved portion may have a radius of curvature of about 1 cm or larger. In some of these embodiments, the curved portion may have a J shape. In some embodiments, the first, second, third, and fourth electrodes may include an exposed portion in electrical contact with the tissue during use. In some of these embodiments, the exposed portion of each of the electrodes may be flat or convex. In some embodiments, the first and second jaws may be parallel.
In some embodiments, a pulse generator may include a controller. The pulse generator may be coupled to the first, second, third, and fourth electrodes. The controller may include a processor and memory. The generator may be configured to generate a pulse waveform of at least about 200 Volts. A first set of electrodes of the first, second, third, and fourth electrodes may be configured for pulse waveform delivery. The pulse waveform may be delivered to the first set of electrodes.
In some embodiments, the generator may be further configured to configure a second set of electrodes of the first, second, third, and fourth electrodes for receiving electrical activity of tissue. Signal data may be received corresponding to electrical activity of the tissue using the second set of electrodes. Electrocardiography data may be generated using the signal data.
In some embodiments, a handle may be coupled to the first jaw and the second jaw. In some of these embodiments, the handle may include one or more of a jaw control, electrode selection control, and pulse waveform control. In some embodiments, a pivot may couple the first jaw to the second jaw. In some embodiments, a spring may be configured to bias the first and second jaws closed. In some embodiments, one or more lead wires may be coupled to the first, second, third, and fourth electrodes.
In some embodiments, a method of ablating tissue via irreversible electroporation may include the steps of clamping tissue between a first jaw and a second jaw of an apparatus. The first jaw may include a plurality of first electrodes and the second jaw may include a plurality of second electrodes. The first jaw and the second jaw may be substantially rigid, elongate, and may collectively define a longitudinal axis. Each electrode of the plurality of first electrodes may have a width orthogonal to the longitudinal axis that is less than a length parallel to the longitudinal axis of that electrode. The plurality of first electrodes may be spaced apart laterally with respect to the longitudinal axis. Each electrode of the plurality of second electrodes may have a width orthogonal to the longitudinal axis that is less than a length parallel to the longitudinal axis of that electrode. The plurality of second electrodes may be spaced apart laterally with respect to the longitudinal axis. An electrode of the plurality of first electrodes may be configured as an anode. An electrode of the plurality of second electrodes may be configured as a cathode. The anode and the cathode may be disposed diagonally across the longitudinal axis and may be spaced apart laterally with respect to the longitudinal axis. Ablative energy may be delivered to the tissue via the anode and the cathode.
In some embodiments, the longitudinal axis may have one or more of a straight portion and curved portion. In some embodiments, clamping the tissue may include transitioning the first and second jaws between a first configuration for advancing the apparatus and a second configuration for clamping the tissue. In some embodiments, the tissue may be a region of the atrial base of a pulmonary vein. In some embodiments, the pulse waveform may include a first level of a hierarchy of the pulsed waveform includes a first set of pulses, each pulse having a pulse time duration, and a first time interval separating successive pulses. A second level of the hierarchy of the pulsed waveform may include a plurality of first sets of pulses as a second set of pulses, a second time interval separating successive first sets of pulses, the second time interval being at least three times the duration of the first time interval. A third level of the hierarchy of the pulsed waveform may include a plurality of second sets of pulses as a third set of pulses, a third time interval separating successive second sets of pulses, the third time interval being at least thirty times the duration of the second level time interval.
In some embodiments, signal data may be received corresponding to electrical activity of the tissue using one or more of the plurality of first electrodes and the plurality of second electrodes. Electrocardiography data may be generated using the signal data. In some embodiments, the first and second jaws may be positioned through or around a body cavity, organ system, or anatomical structure. In some embodiments, each electrode of the plurality of first electrodes and the plurality of second electrodes may be independently addressable.
Described herein are systems, devices, and methods for selective and rapid application of pulsed electric fields to ablate tissue by irreversible electroporation. Generally, the systems, devices, and methods described herein may be used to generate electric field magnitudes at desired regions of interest while tissue is clamped (e.g., held) in order to treat atrial fibrillation via irreversible electroporation. An ablation device may include a set of jaws or arms each having a set of electrodes that may be configured to hold (e.g., clamp, grasp, compress) a portion of tissue therebetween and provide tissue ablation with reduced energy delivery. The set of electrodes may be configured to contact tissue during use. The jaws may transition from a closed configuration to an open configuration for grasping tissue such as a pulmonary vein. It is understood that the set of jaws may be transformed into any intermediate configuration between the open and closed configurations, continuously or in discrete steps. For example, the jaws may transition from a closed configuration to an open configuration to allow tissue to be placed between the jaws. Then, the jaws may be brought closer together to apply compression force to tissue disposed therebetween to target energy delivery to a desired portion of tissue.
An irreversible electroporation system as described herein may include a signal generator and a processor configured to apply one or more voltage pulse waveforms to a selected set of electrodes of an ablation device (e.g., clamp, clip, forcep, hemostat) to deliver energy to a region of interest (e.g., portion of a pulmonary vein) and provide a highly configurable a set of electrode channels (e.g., allow independent and arbitrary electrode selection). The ablation device may generally include a pair of opposable members configured to hold tissue therebetween. In some embodiments, the opposable members may be movable relative to each other. The pulse waveforms disclosed herein may aid in therapeutic treatment of a variety of cardiac arrhythmias (e.g., atrial fibrillation). In order to deliver the pulse waveforms generated by the signal generator, the ablation device may comprise one or more elongate parallel electrodes. In some embodiments, the electrodes may be independently addressable such that each electrode may be controlled (e.g., deliver energy) independently of any other electrode of the device. For example, an anode-cathode energy delivery sequence may be selected to ablate desired regions of tissue and/or to reduce the possibility of shorting. In this manner, the electrodes may deliver different energy waveforms with different timing synergistically for electroporation of tissue.
The term “electroporation” as used herein refers to the application of an electric field to a cell membrane to change the permeability of the cell membrane to the extracellular environment. The term “reversible electroporation” as used herein refers to the application of an electric field to a cell membrane to temporarily change the permeability of the cell membrane to the extracellular environment. For example, a cell undergoing reversible electroporation may observe the temporary and/or intermittent formation of one or more pores in its cell membrane that close up upon removal of the electric field. The term “irreversible electroporation” as used herein refers to the application of an electric field to a cell membrane to permanently change the permeability of the cell membrane to the extracellular environment. For example, a cell undergoing irreversible electroporation may observe the formation of one or more pores in its cell membrane that persist upon removal of the electric field.
Pulse waveforms for electroporation energy delivery as disclosed herein may enhance the safety, efficiency, and effectiveness of energy delivery to tissue by reducing the electric field threshold associated with irreversible electroporation, thus yielding more effective ablative lesions with a reduction in total energy delivered. In some embodiments, the voltage pulse waveforms disclosed herein may be hierarchical and have a nested structure. For example, the pulse waveform may include hierarchical groupings of pulses having associated timescales. In some embodiments, the methods, systems, and devices disclosed herein may comprise one or more of the methods, systems, and devices described in International Application Serial No. PCT/US2016/057664, filed on Oct. 19, 2016, and titled “SYSTEMS, APPARATUSES AND METHODS FOR DELIVERY OF ABLATIVE ENERGY TO TISSUE,” and U.S. application Ser. No. 15/796,375, filed on Oct. 27, 2017, and titled “SYSTEMS, APPARATUSES AND METHODS FOR DELIVERY OF ABLATIVE ENERGY TO TISSUE,” the contents of each of which are hereby incorporated by reference in their entirety.
In some embodiments, the systems may further include a cardiac stimulator used to synchronize the generation of the pulse waveform to a paced heartbeat. The cardiac stimulator may electrically pace the heart with a cardiac stimulator and ensure pacing capture to establish periodicity and predictability of the cardiac cycle. A time window within a refractory period of the periodic cardiac cycle may be selected for voltage pulse waveform delivery. Thus, voltage pulse waveforms may be delivered in the refractory period of the cardiac cycle to avoid disruption of the sinus rhythm of the heart. The ablation device may transform into different configurations (e.g., compact and expanded) to navigate and position the device within a body cavity. In some embodiments, the system may optionally include one or more return electrodes.
Generally, to ablate tissue, the device may be surgically placed at a target location. In a cardiac application, the electrodes through which the voltage pulse waveform is delivered may be disposed on opposing sides of a pair of jaws of an ablation device. The methods described here may include placing tissue (e.g., pulmonary vein) between the jaws in contact with the electrodes. A pulse waveform may be generated and delivered to one or more electrodes of the device to ablate tissue. In some embodiments, the pulse waveform may be generated in synchronization with a pacing signal of the heart to avoid disruption of the sinus rhythm of the heart. In some embodiments, the electrodes may be configured in anode-cathode (e.g., bipole) subsets. The pulse waveform may include hierarchical waveforms to aid in tissue ablation and reduce damage to healthy tissue.
I. Systems
Disclosed herein are systems and devices configured for tissue ablation via the selective and rapid application of voltage pulse waveforms to aid tissue ablation, resulting in irreversible electroporation. Generally, a system for ablating tissue described here may include a signal generator and an ablation device having one or more electrodes for the selective and rapid application of DC voltage to drive electroporation. Voltages may be applied to a selected subset of the electrodes, with independent subset selections for anode and cathode electrode selections. The ablation device may be coupled to one or more electrode channels of the signal generator. Each electrode channel may be independently configured as an anode or cathode and a voltage pulse waveform may be delivered through one or more of the electrode channels in a predetermined sequence. A pacing signal for cardiac stimulation may be generated and used to generate the pulse waveform by the signal generator in synchronization with the pacing signal.
Generally, the systems and devices described herein include one or more ablation devices configured to ablate tissue held between jaws of the device.
In some embodiments, the actuator may be configured for direct movement of the jaws such that when engaged, the actuator causes the jaws to move in a 1:1 ratio or some other ratio. That is, the actuator may be configured to limit, attenuate, and/or amplify a force applied by the jaws based on an amount of force applied to the actuator. In some embodiments, the ablation device (740) may include a spring configured to bias the jaws (710, 720) between different configurations. For example, a spring may be coupled to the jaws (710, 720) and be configured to bias the jaws (710, 720) towards the tissue ablation configuration in order to apply a compressive force to tissue held between the jaws (710, 720) when the ablation device is advanced into or retracted from a body cavity, the jaws may transition to a closed configuration where the jaws contact each other.
The signal generator (610) may be configured to generate pulse waveforms for irreversible electroporation of tissue, such as, for example, heart tissue. The signal generator (610) may be a voltage pulse waveform generator and deliver a pulse waveform to a set of electrodes (642a, 642b, . . . , 642n, and 644a, 644b, . . . , 644n) of the ablation device (640). The signal generator (610) may generate and deliver several types of signals including, but not limited to, radiofrequency (RF), direct current (DC) impulses (such as high-voltage, ultra-short pulses used in electroporation), stimulus range impulses, and/or hybrid electrical impulses. For example, the signal generator (610) may generate monophasic (DC) pulses or biphasic pulses (pulses of both polarities). The signal generator (610) may include a processor (620), memory (622), a set of electrode channels (624a, 624b, . . . , 624n, and 625a, 625b, . . . , 625n), energy source (626), sensing circuit (628), routing console (630), and user interface (632). One or more signal generator components may be coupled using a communication bus. The processor (620) may incorporate data received from one or more of memory (622), electrode channels (624a, 624b, . . . , 624n, and 625a, 625b, . . . , 625n), energy source (626), sensing circuit (628), routing console (630), user interface (632), ablation device (640), and cardiac stimulator (650) to determine the parameters (e.g., amplitude, width, duty cycle, timing, etc.) of the voltage pulse waveform to be generated by the signal generator (610). The memory (622) may further store instructions to cause the processor (620) to execute modules, processes and/or functions associated with the system (600), such as pulse waveform generation and delivery, electrode channel configuration, and/or cardiac pacing synchronization. For example, the memory (622) may be configured to store anode/cathode configuration data, electrode channel configuration data, pulse waveform data, fault data, energy discharge data, heart pacing data, patient data, clinical data, procedure data, electromyography data, sensor data, temperature data, and/or the like.
In some embodiments, the ablation device (640) may include a catheter configured to receive and/or deliver the pulse waveforms described herein. For example, the ablation device (640) may be introduced into an epicardial space of the left atrium and positioned to align one or more electrodes (642a, 642b, . . . , 642n, and 644a, 644b, . . . , 644n) to heart tissue (e.g., pulmonary vein), and then deliver the pulse waveforms to ablate tissue. The ablation device (140) may include one or more electrodes (642a, 642b, . . . , 642n, and 644a, 644b, . . . , 644n), which may, in some embodiments, be a set of independently addressable electrodes. For example, the electrodes (642a, 642b, . . . , 642n, and 644a, 644b, . . . , 644n) may be grouped into one or more anode-cathode subsets such as, for example, a subset including one anode and one cathode, a subset including two anodes and two cathodes, a subset including two anodes and one cathode, a subset including one anode and two cathodes, a subset including three anodes and one cathode, a subset including three anodes and two cathodes, and/or the like. The set of electrodes (642a, 642b, . . . , 642n, and 644a, 644b, . . . , 644n) may include any number of electrodes, for example, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, or more electrodes. In some embodiments, the methods, systems, and devices disclosed herein may comprise one or more of the methods, systems, and devices described in International Patent Application Serial No. PCT/US2018/029552, filed on Apr. 26, 2018, and titled “SYSTEMS, DEVICES, AND METHODS FOR SIGNAL GENERATION,” International Application Serial No. PCT/US2019/014226, filed on Jan. 18, 2019, and titled “SYSTEMS, DEVICES, AND METHODS FOR FOCAL ABLATION,” and International Application Serial No. PCT/US2013/031252, filed on Mar. 14, 2013, and titled “CATHETERS, CATHETER SYSTEMS, AND METHODS FOR PUNCTURING THROUGH A TISSUE STRUCTURE AND ABLATING A TISSUE REGION,” the contents of which are hereby incorporated by reference in their entirety.
In some embodiments, the processor (620) may be any suitable processing device configured to run and/or execute a set of instructions or code and may include one or more data processors, image processors, graphics processing units, physics processing units, digital signal processors, and/or central processing units. The processor (620) may be, for example, a general purpose processor, Field Programmable Gate Array (FPGA), an Application Specific Integrated Circuit (ASIC), and/or the like. The processor (620) may be configured to run and/or execute application processes and/or other modules, processes and/or functions associated with the system and/or a network associated therewith (not shown). In some embodiments, the processor may comprise both a microcontroller unit and an FPGA unit, with the microcontroller sending electrode sequence instructions to the FPGA. The underlying device technologies may be provided in a variety of component types, e.g., metal-oxide semiconductor field-effect transistor (MOSFET) technologies like complementary metal-oxide semiconductor (CMOS), bipolar technologies like emitter-coupled logic (ECL), polymer technologies (e.g., silicon-conjugated polymer and metal-conjugated polymer-metal structures), mixed analog and digital, and/or the like.
In some embodiments, the memory (622) may include a database (not shown) and may be, for example, a random access memory (RAM), a memory buffer, a hard drive, an erasable programmable read-only memory (EPROM), an electrically erasable read-only memory (EEPROM), a read-only memory (ROM), Flash memory, etc. The memory (622) may store instructions to cause the processor (620) to execute modules, processes and/or functions associated with the system (600), such as pulse waveform generation, electrode channel configuration, and/or cardiac pacing.
In some embodiments, a set of electrode channels (624a, 624b, . . . , 624n, and 625a, 625b, . . . , 625n) may include a set of active solid-state switches. The set of electrode channels (624a, 624b, . . . , 624n, and 625a, 625b, . . . , 625n) may be configured in a number of ways, including independent anode/cathode configuration for each electrode channel. For example, the electrode channels (624a, 624b, . . . , 624n, and 625a, 625b, . . . , 625n) may be grouped into one or more anode-cathode subsets such as, for example, a subset including one anode and one cathode, a subset including two anodes and two cathodes, a subset including two anodes and one cathode, a subset including one anode and two cathodes, a subset including three anodes and one cathode, a subset including three anodes and two cathodes, and/or the like. The set of electrode channels (624a, 624b, . . . , 624n, and 625a, 625b, . . . , 625n) may include any number of channels, for example, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, or more electrode channels. Energy delivery may use any combination of electrode channels (624a, 624b, . . . , 624n, and 625a, 625b, . . . , 625n) and any order for an energy delivery sequence.
The set of electrode channels (624a, 624b, . . . , 624n, and 625a, 625b, . . . , 625n) may be coupled to a routing console (630) to deliver energy to a set of electrodes (642) coupled to the routing console (630). The set of electrode channels (624a, 624b, . . . , 624n, and 625a, 625b, . . . , 625n) may be coupled to an energy source (626) to receive energy (e.g., a pulse waveform). Processor (620) may be coupled to each electrode channel (624a, 624b, . . . , 624n, and 625a, 625b, . . . , 625n) to configure an anode/cathode configuration for each electrode channel (624), which may be configured on a per pulse basis, per operator input, and/or the like. The processor (620) and energy source (626) may be collectively configured to deliver a pulse waveform to the set of electrodes (642, 644) through the set of electrode channels (624a, 624b, . . . , 624n, and 625a, 625b, . . . , 625n). In some embodiments, each electrode channel (624a, 624b, . . . , 624n, and 625a, 625b, . . . , 625n) may include an electronic switch (e.g., bipolar transistor) and a drive circuit, as described in detail herein. In some embodiments, each electrode channel (624a, 624b, . . . , 624n, and 625a, 625b, . . . , 625n) may have a bootstrap configuration for low and high frequency operation. For example, the pulse duration of voltage pulses delivered through an electrode channel may be in the range of between about 1 microsecond and about 1000 microseconds. In biphasic mode, this corresponds to an approximate frequency range of between about 500 Hz and about 500 KHz for the frequency associated with the voltage pulses.
In some embodiments, a pulse generator including a controller with the processor (620) and memory (622) may be coupled to each electrode of the set of first electrodes (642) and the set of second electrodes (644). The pulse generator and/or controller may be configured to generate a pulse waveform, configure a first set of electrodes of the set of first electrodes (642) and the set of second electrodes (644) for pulse waveform delivery. The pulse waveform may be delivered to the first set of electrodes (642). In some embodiments, a second set of electrodes of the set of first electrodes (642) and the set of second electrodes (644) may be configured for receiving electrical activity of tissue. Signal data corresponding to the electrical activity of the tissue may be received using the second set of electrodes. Electrocardiography data may be generated using the signal data.
In some embodiments, an energy source (626) may be configured to convert and supply energy to a set of electrodes (642, 644) coupled to the signal generator (610). The energy source (626) of the signal generator (610) may include a DC power supply and be configured as an AC/DC switcher. In some embodiments, an energy source (626) of the signal generator (610) may deliver rectangular-wave pulses with a voltage in the range between about 300 V and about 5000 V. In some of these embodiments, the energy source (626) may be configured to store energy. For example, the energy source (626) may include one or more capacitors to store energy from a power supply. While these examples are included for purely non-limiting illustrative purposes, it is noted that a variety of pulse waveforms with a range of pulse durations, intervals between pulses, pulse groupings, etc. may be generated depending on the clinical application.
In some embodiments, a sensing circuit (628) may be configured to determine an amount of current being delivered to a device coupled to the signal generator (610) (e.g., electrode (642) coupled to the electrode channel (624)). As described in more detail herein, the sensing circuit (628) may also be used to classify an electrode channel fault, monitor capacitor discharge, and/or sense arcing. In some embodiments, the sensing circuit (628) may be a direct current sensing circuit and/or a low-side sensing circuit. The sensing circuit may include one or more operational amplifiers, difference amplifiers (DA), instrumentation amplifiers (IA), and/or current shunt monitors (CSM).
In some embodiments, the routing console (630) may be configured to electrically couple a set of electrodes (642) of an ablation device (640) to a set of electrode channels (624a, 624b, . . . , 624n, and 625a, 625b, . . . , 625n). The routing console (630) may be configured to selectively deliver energy to the set of electrodes (642) using the set of electrode channels (624a, 624b, . . . , 624n, and 625a, 625b, . . . , 625n). One or more ablation devices (640) each having a set of electrodes (642, 644) may be coupled to the routing console (630). The set of electrodes (642, 644) may include any number of electrodes, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, or more electrodes. In some embodiments, an ablation device (640) may include three electrodes with a first jaw (650a) having a first electrode (642a) and a second jaw (650b) having a second electrode (644a) and a third electrode (644b).
In some embodiments, the electrode channels (624a, 624b, . . . , 624n, and 625a, 625b, . . . , 625n) configured for energy delivery (e.g., configured as an anode/cathode pair of electrode channels) may not be adjacent to each other. For example, the set of electrode channels (624a, 624b, . . . , 624n, and 625a, 625b, . . . , 625n) may include a set of N electrode channels (624a, 624b, . . . , 624n, and 625a, 625b, . . . , 625n) in a parallel array. In one embodiment, a first electrode channel may correspond to a first electrode channel (624a) in the parallel array of N electrode channels (624a, 624b, . . . , 624n, and 625a, 625b, . . . , 625n). One or more of a second and third electrode channel (624b, 624c) may not be adjacent to the first electrode channel (624a) in the parallel array of N electrode channels (624a, 624b, . . . , 624n, and 625a, 625b, . . . , 625n).
A multi-electrode ablation device may allow targeted and precise energy delivery to tissue. In some embodiments, the electrodes (642, 644) of an ablation device (640) may be configured for energy delivery (e.g., as an anode/cathode pair of electrodes (642, 644)) and may be disposed on opposing jaws on respective parallel arrays of the ablation device (640). For example, an ablation device (640) may include a first jaw (650a) having a set of first electrodes (642) as a parallel array of N electrodes (142n) and a second jaw (650b) having a set of second electrodes (644) as a parallel array of M electrodes (644n). The signal generator (610) coupled to the ablation device (640) may include a set of electrode channels (624a, 624b, . . . , 624n, and 625a, 625b, . . . , 625n) having N electrode channels corresponding to the M electrodes (642n, 644n) of the ablation device (640). In one embodiment, the first electrode channel (624a) of the N electrode channels (624a, 624b, . . . , 624n, and 625a, 625b, . . . , 625n) may correspond to a first electrode (642a) in the parallel array of M electrodes (642n) of the first jaw (650a). One or more of second and third electrode channel (624b, 624c) of the N electrode channels (624n) may not correspond to any of the electrodes adjacent to the first electrode (642a) in the parallel array of M electrodes (642n). For example, the second electrode channel (642b) may correspond to a second electrode (644a) in the parallel array of M electrodes (644n) of the second jaw (650b).
Configurable electrode channel and electrode selection may provide flexibility in positioning the electrodes for ablating a desired region of interest, as described in more detail herein. In some embodiments, the routing console (630) may couple to a set of four or six electrodes (642, 644) of an ablation device (640). The routing console (630) may receive input from the processor (620) and/or user interface (632) for electrode channel selection and energy delivery to one or more electrodes (642, 644). Additionally or alternatively, the routing console (630) may couple to a cardiac stimulator (650) and be configured to receive data from devices (e.g., heart pacing data from a pacing device) used for synchronization of a pulse waveform with a patient cardiac cycle.
In some embodiments, a user interface (632) may be configured as a communication interface between an operator and the system (600). The user interface (632) may include an input device and output device (e.g., touch surface and display). For example, patient data from memory (622) may be received by user interface (632) and output visually and/or audibly. Electric current data from sensing circuit (628) may be received and output on a display of user interface (632). As another example, operator control of an input device having one or more buttons, knobs, dials, switches, trackball, touch surface, and/or the like, may generate a control signal to the signal generator (610) and/or ablation device (640).
In some embodiments, an input device of the user interface (632) may include a touch surface for operator input and may be configured to detect contact and movement on the touch surface using any of a plurality of touch sensitivity technologies including capacitive, resistive, infrared, optical imaging, dispersive signal, acoustic pulse recognition, and surface acoustic wave technologies. Additionally or alternatively, the user interface (632) may include a step switch or foot pedal.
In some embodiments, an output device of the user interface (632) may include one or more of a display device and audio device. The display device may include at least one of a light emitting diode (LED), liquid crystal display (LCD), electroluminescent display (ELD), plasma display panel (PDP), thin film transistor (TFT), and organic light emitting diodes (OLED). An audio device may audibly output patient data, sensor data, system data, other data, alarms, warnings, and/or the like. The audio device may include at least one of a speaker, piezoelectric audio device, magnetostrictive speaker, and/or digital speaker. In one embodiment, the audio device may output an audible warning upon detection of a fault in the signal generator (610) and/or ablation device (640).
In some embodiments, the signal generator (610) may be mounted on a trolley or cart. In some embodiments, the user interface (632) may be formed in the same or different housing as the signal generator (610). The user interface (632) may be mounted to any suitable object, such as furniture (e.g., a bed rail), a wall, a ceiling, or may be self-standing. In some embodiments, the input device may include a wired and/or wireless transmitter configured to transmit a control signal to a wired and/or wireless receiver of the signal generator (610).
In some embodiments, a cardiac stimulator (650) including a pacing device may be configured to generate a heart pacing signal to be delivered to a patient via the pacing device. An indication of the pacing signal may be transmitted by the cardiac stimulator (650) to the signal generator (610). Based on the pacing signal, an indication of a voltage pulse waveform may be selected, computed, and/or otherwise identified by the processor (620) and generated by the signal generator (610). In some embodiments, the signal generator (610) may be configured to generate the voltage pulse waveform in synchronization with the indication of the pacing signal (e.g., within a common refractory window). For example, in some embodiments, the common refractory window may start substantially immediately following a ventricular pacing signal (or after a very small delay) and last for a duration of between about 150 ms and about 250 ms thereafter. In such embodiments, an entire pulse waveform may be delivered within this duration.
In some embodiments, the systems described herein may include one or more sterile coverings configured to create a sterile barrier around portions of the system (600). In some embodiments, the system (600) may include one or more sterile coverings to form a sterile field. For example, a sterile covering may be placed over the user interface of the signal generator. The sterile covering may include, for example, a sterile drape configured to cover at least a portion of a system component. In one embodiment, a sterile covering (e.g., sterile drape) may be configured to create a sterile barrier with respect to a user interface (632) of the system (600). The sterile drape may be clear and allow an operator to visualize and manually manipulate the user interface (632). The sterile covering may conform tightly around one or more system components or may drape loosely to allow components to be adjusted within the sterile field.
The systems described here may include one or more multi-electrode ablation devices configured to ablate tissue for treating atrial fibrillation. Generally, the ablation devices may include a first jaw and a second jaw sized and shaped to physically engage, hold, and (optionally) compress tissue therebetween for delivery of ablation energy. In some embodiments, a distal end of the first jaw and the second jaw may be generally atraumatic to decrease the risk of damage to tissue through laceration, puncture, and other damage when releasably coupled thereto. For example, the first jaw and second jaw may form atraumatic surfaces and edges (e.g., rounded, blunt) to contact and/or hold tissue without causing damage. A set of metallic electrodes disposed on each of the jaws and may also be generally atraumatic to decrease the risk of damage to tissue through laceration and puncture. For example, the edges of the electrodes may be rounded to reduce tissue damage and to increase the uniformity of the electric field generated at a central portion and a peripheral portion of the electrodes. The electrodes may generally form an elongate member (e.g., bar, strip) that extends generally parallel to a length of the jaws. The electrodes may have a length greater than a width or height/depth dimension of the electrode. The jaws as described in more detail herein may be composed of an electrically insulating material such as a polymeric or ceramic material.
In order to deliver the pulse waveforms generated by the signal generator, one or more electrodes of the ablation device may have an insulated electrical lead configured for sustaining a voltage potential of at least about 300 V without dielectric breakdown of its corresponding insulation. In some embodiments, the insulation on each of the electrical leads may sustain an electrical potential difference of between about 200 V to about 3,000 V across its thickness without dielectric breakdown, including all values and sub-ranges in between. In some embodiments, the electrodes may be independently addressable such that each electrode may be controlled (e.g., deliver energy) independently of any other electrode of the device. In this manner, the electrodes may deliver different energy waveforms with different timing synergistically for electroporation of tissue. The electrodes may, for example, be connected to an insulated electrical lead leading to a handle to receive pulse waveforms generated by a signal generator as discussed above with respect to
The set of first electrodes (110) and the set of second electrodes (120) may be arranged parallel to the longitudinal axis (140) of the jaws (102, 104). Each of the first electrodes (110) may be spaced apart from an adjacent first electrode (110) by a first measure (106) (e.g., spacing, distance) and each of the second electrodes (120) may be spaced apart from an adjacent second electrode (120) by a second measure (108). The set of first electrodes (110) may be disposed on a side of the first jaw (102) facing the second jaw (104) with each of the set of first electrodes (110) spaced apart laterally with respect to the longitudinal axis (140). Similarly, the set of second electrodes (120) may be disposed on a side of the second jaw (104) facing the first jaw (102) with each of the set of second electrodes (120) spaced apart laterally with respect to the longitudinal axis (140). As shown in
At least two of the set of first electrodes (110) may be spaced apart by a first measure (106), and at least two of the set of second electrodes (120) may be spaced apart by a second measure (108), as shown in
In some embodiments, each electrode of the set of first electrodes (110) and the set of second electrodes (120) may have a width orthogonal to the longitudinal axis that is less than a length of that electrode that is parallel to the longitudinal axis (140) where the set of first electrodes (110) are spaced apart laterally with respect to the longitudinal axis (140). In particular, each electrode of the set of first electrodes (110) has, within a cross-section of the apparatus (e.g., a cross-section of the first jaw (102) and the second jaw (104)) that is orthogonal to the longitudinal axis, a width that is less than a length of that electrode, where the set of first electrodes (110) are spaced apart laterally. In some embodiments, any two adjacent electrodes of the set of first electrodes (110) may have a first measure of between about 0.5 mm and about 10 mm and any two adjacent electrodes of the set of second electrodes (120) may have a second measure of between about 0.5 mm and about 10 mm.
In some embodiments, each electrode of the set of first electrodes (110) and the set of second electrodes (120) may have a length of between about 1 cm and about 8 cm, a width of between about 1 mm and about 5 mm, and a height of between about 0.5 mm and about 3 mm. In some embodiments, the set of first electrodes (110) and the set of second electrodes (120) may have a length to width ratio of at least about 3:1.
The set of first electrodes (110) and the set of second electrodes (120) may have a shape of an elongate electrode. In some embodiments, each electrode of the set of first electrodes (110) and the set of second electrodes (120) may be substantially rectangular, e.g., have a cross-sectional shape that is rectangular. In other embodiments, each electrode of the set of first electrodes (110) and the set of second electrodes (120) may include a curved portion.
In some embodiments, each electrode of the set of first electrodes (110) and the set of second electrodes (120) may be independently addressable. One or more lead wires may be coupled to the set of first electrodes (110) and the set of second electrodes (120). In some embodiments, the electrodes may comprise a generally elliptical or circular cross-section. A length of a semi-major axis of the electrode may be between about 0.5 mm and about 5 mm. In some of these embodiments, a length to width ratio of the electrode may be at least about 3:1.
In some embodiments, an electrode of the set of first electrodes (110) may be configured as an anode and an electrode of the set of second electrodes (120) may be configured as a cathode. For example, the anode may be disposed directly across from the cathode. For example, a first electrode pairing may include electrodes (110a, 120a) directly across from each other on opposing jaws (102, 104) within the cross-section of
In other embodiments, the anode may be diagonal from the cathode within the cross-section orthogonal to the longitudinal axis. In some embodiments, the anode may generally be spaced apart laterally from the cathode with respect to the longitudinal axis. In some embodiments, a first electrode pairing may include electrodes (110a, 120b) spaced apart laterally from each other on opposing jaws (102, 104) within the cross-section orthogonal to the longitudinal axis and a second electrode pairing may include electrodes (110b, 120a) spaced apart laterally from each other on opposing jaws (102, 104) with respect to the longitudinal axis, and so forth for n electrodes.
In some embodiments, one electrode of the set of first electrodes (110) may be configured as an anode while another electrode of the set of first electrodes (110) may be configured as a cathode. In some embodiments, one electrode of one of the jaws may be configured as an anode while another electrode of the same jaw may be configured as a cathode. In some embodiments, a first electrode pairing may include electrodes (110a, 110b) adjacent to each other on the same first jaw (102) within the cross-section orthogonal to the longitudinal axis, a second electrode pairing may include electrodes (120a, 120b) adjacent to each other on the same second jaw (104) within the cross-section orthogonal to the longitudinal axis, and so forth for n electrodes.
A pre-determined ablation sequence may include delivering ablation pulse waveforms over a sequence of pre-defined electrode pairings. In some embodiments, the sequenced delivery may be triggered from a cardiac stimulator and/or pacing device. In some embodiments, the ablation pulse waveforms may be applied in a refractory period of the cardiac cycle to avoid disruption of the sinus rhythm of the heart, as described in more detail herein. One or more of the electrodes may be configured to receive signal data corresponding to electrical activity of the tissue (e.g., electrocardiography data).
In some embodiments, a handle such as the handle shown in
A distal end of the first jaw (810) may include a set of first electrodes such as the two electrodes (812a, 812b) shown in
The first electrodes (812a, 812b) may be disposed on a side of the first jaw (810) facing the second jaw (820). Similarly, the second electrodes (822a, 822b) may be disposed on a side of the second jaw (820) facing the first jaw (810). Each electrode of the first electrodes (812a, 812b) and the second electrodes (822a, 822b) may include an exposed portion in electrical contact with tissue during use. The exposed portion of each electrode of the first electrodes (812a, 812b) and the second electrodes (822a, 822b) may be flat or convex. Each electrode (812a, 812b, 822a, 822b) may have an insulated electrical lead associated therewith. The insulated electrical leads may be disposed in a corresponding shaft. In some embodiments, each electrode of the set of first electrodes (812) and the set of second electrodes (822) may be independently addressable. In some embodiments, the electrodes (812a, 812b, 822a, 822b) may have a length of between about 1 cm and about 8 cm, a width of between about 1 mm and about 5 mm, and a height of between about 0.5 mm and about 3 mm. In some embodiments the electrodes (812a, 812b, 822a, 822b) may have a length to width ratio of at least about 3:1.
In some embodiments, an electrode of the set of first electrodes (812) may be configured as an anode and an electrode of the set of second electrodes (822) may be configured as a cathode. For example, the anode may be disposed directly across from the cathode within the cross-section orthogonal to the longitudinal axis. In some embodiments, a first electrode pairing may include electrodes (812a, 822a) directly across from each other on opposing jaws (810, 820) within the cross-section orthogonal to the longitudinal axis and a second electrode pairing may include electrodes (812b, 822b) directly across from each other on opposing jaws (810, 820) within the cross-section orthogonal to the longitudinal axis.
In other embodiments, the anode may be diagonal from the cathode such that the anode is laterally spaced apart from the cathode with respect to the longitudinal axis and/or does not intersect a line perpendicular to the cathode. In some embodiments, a first electrode pairing may include electrodes (812a, 822b) spaced apart laterally from each other on opposing jaws (810, 820) and a second electrode pairing may include electrodes (812b, 822a) spaced apart laterally from each other on opposing jaws (810, 820) with respect to the longitudinal axis. This combination of electrode pairing may reduce, if not eliminate, the risk of the electrodes electrically shorting in cases where tissue is incompletely grasped between the jaws and/or portions of the jaws touch each other.
In some embodiments, one electrode of one of the jaws may be configured as an anode while another electrode of the same jaw may be configured as a cathode. In some embodiments, a first electrode pairing may include electrodes (812a, 812b) adjacent to each other on the same jaw (810) and a second electrode pairing may include electrodes (822a, 822b) adjacent to each other on the same jaw (820).
Generally in the embodiments described herein, pulsed electric field ablation is delivered in order to generate irreversible electroporation in the tissue between the jaws. A pre-determined ablation sequence may include delivering ablation pulse waveforms sequentially over a pre-defined set of electrode pairings, for example first and second electrode pairings when a set of two electrode pairings are configured. In some embodiments, the sequenced delivery may be triggered from a cardiac stimulator and/or pacing device. In some embodiments, the ablation pulse waveforms may be applied in a refractory period of the cardiac cycle to avoid disruption of the sinus rhythm of the heart, as described in more detail herein. One or more of the electrodes may be configured to receive signal data corresponding to electrical activity of the tissue (e.g., electrocardiography data).
In some embodiments, a handle such as the handle shown in
A distal end of the first jaw (910) may include a set of first electrodes such as the three electrodes (912a, 912b, 912c) shown in
Each of the first electrodes (912a, 912b, 912c) may be spaced apart from each other within the cross-section orthogonal to the longitudinal axis and each of the second electrodes (922a, 922b, 922c) may be spaced apart from each other within the cross-section orthogonal to the longitudinal axis. The set of first electrodes (912) and the set of second electrodes (922) may be elongate electrodes. In some embodiments, each electrode of the set of first electrodes (912) and the set of second electrodes (922) may be substantially rectangular. In other embodiments, each electrode of the set of first electrodes (912) and the set of second electrodes (922) may include a curved portion such as a generally arcuate shape or rounded edges. The electrodes may include a curvature such that generally each electrode follows the curvature of its respective jaw.
The first electrodes (912a, 912b, 912c) may be disposed on a side of the first jaw (910) facing the second jaw (920). Similarly, the second electrodes (922a, 922b, 922c) may be disposed on a side of the second jaw (920) facing the first jaw (910). Each electrode of the first electrodes (912a, 912b, 912c) and the second electrodes (922a, 922b, 922c) may include an exposed portion in electrical contact with tissue during use (
In some embodiments, an electrode of the set of first electrodes (912) may be configured as an anode and an electrode of the set of second electrodes (922) may be configured as a cathode. For example, the anode may be disposed directly across from the cathode. In some embodiments, a first electrode pairing may include electrodes (912a, 922a) directly across from each other on opposing jaws (910, 920), a second electrode pairing may include electrodes (912b, 922b) directly across from each other on opposing jaws (810, 820), and a third electrode pairing may include electrodes (912c, 922c) directly across from each other on opposing jaws (910, 920).
In other embodiments, the anode may be diagonal from the cathode within the cross-section orthogonal to the longitudinal axis such that the anode is laterally spaced apart from the cathode with respect to the longitudinal axis and/or does not intersect a line perpendicular to the cathode. In some embodiments, a first electrode pairing may include electrodes (912a, 922b) spaced apart laterally from each other on opposing jaws (910, 920) with respect to the longitudinal axis, a second electrode pairing may include electrodes (912b, 922a) spaced apart laterally from each other on opposing jaws (910, 920) with respect to the longitudinal axis, a third electrode pairing may include electrodes (912b, 922c) spaced apart laterally from each other on opposing jaws (910, 920) with respect to the longitudinal axis, and a fourth electrode pairing may include electrodes (912c, 922b) spaced apart laterally from each other on opposing jaws (910, 920) with respect to the longitudinal axis.
In some embodiments, one electrode of one of the jaws may be configured as an anode while another electrode of the same jaw may be configured as a cathode. In some embodiments, a first electrode pairing may include electrodes (912a, 912b) adjacent to each other on the same first jaw (910), a second electrode pairing may include electrodes (912b, 912c) adjacent to each other on the same first jaw (910), a third electrode pairing may include electrodes (922a, 922b) adjacent to each other on the same second jaw (920), and a fourth electrode pairing may include electrodes (922b, 922c) adjacent to each other on the same second jaw (920).
A pre-determined ablation sequence may include delivering ablation pulse waveforms sequentially over a pre-defined set of electrode pairings. In some embodiments, the sequenced delivery may be triggered from a cardiac stimulator and/or pacing device. In some embodiments, the ablation pulse waveforms may be applied in a refractory period of the cardiac cycle to avoid disruption of the sinus rhythm of the heart, as described in more detail herein. One or more of the electrodes may be configured to receive signal data corresponding to electrical activity of the tissue (e.g., electrocardiography data).
In some embodiments, a handle such as the handle shown in
The electrodes as described may be composed of any suitable biocompatible conductive material including, but not limited to, one or more of silver, palladium, stainless steel, platinum, titanium, platinum-iridium alloys, gold, copper, nickel, combinations thereof, and the like. In some embodiments, the electrode materials may be plated, coated, and/or otherwise applied in an appropriately thick layer on top of a different substrate material. In some embodiments, electrode portions may be coupled using annealing, soldering, welding, crimping, lamination, combinations thereof, and the like. The jaws and body of the ablation devices disclosed may be composed of any suitable electrically insulating biocompatible material including polymers, ceramics, glasses, combinations thereof, and the like.
II. Methods
Also described here are methods for ablating tissue (e.g., pulmonary vein) using the systems and devices described above. The ablation devices described herein may be used for ablation of cardiac features/structures identified to cause arrhythmia. The pulmonary vein may be connected to the left atrium of the heart. Generally, the methods described here include introducing and disposing a device in contact with one or more pulmonary vein regions. A pulse waveform may be delivered by one or more electrodes of the device to ablate tissue. In some embodiments, a cardiac pacing signal may synchronize the delivered pulse waveforms with the cardiac cycle. Additionally or alternatively, the pulse waveforms may include a set of levels of a hierarchy. The tissue ablation thus performed may be delivered in synchrony with paced heartbeats. It should be appreciated that any of the ablation devices described herein may be used to ablate tissue using the methods discussed below as appropriate.
As a non-limiting example, in some embodiments, a system may include any of the devices described in the disclosure herein.
Returning to
In some embodiments, a pacing signal may be generated for cardiac stimulation of the heart. The pacing signal may then be applied to the heart. For example, the heart may be electrically paced with a cardiac stimulator to ensure pacing capture to establish periodicity and predictability of the cardiac cycle. One or more of atrial and ventricular pacing may be applied. An indication of the pacing signal may be transmitted to a signal generator. A time window within the refractory period of the cardiac cycle may then be defined within which one or more voltage pulse waveforms may be delivered. In some embodiments, a refractory time window may follow a pacing signal. For example, a common refractory time window may lie between both atrial and ventricular refractory time windows.
A pulse waveform may be generated in synchronization with the pacing signal (1108). For example, a voltage pulse waveform may be applied in the common refractory time window. In some embodiments, the pulse waveform may be generated with a time offset with respect to the indication of the pacing signal. For example, the start of a refractory time window may be offset from the pacing signal by a time offset. The voltage pulse waveform(s) may be applied over a series of heartbeats over corresponding common refractory time windows.
In some embodiments, hierarchical voltage pulse waveforms having a nested structure and a hierarchy of time intervals as described herein may be useful for irreversible electroporation, providing control and selectivity in different tissue types. A pulse waveform may be generated by a signal generator (e.g., the signal generator 610) and may include a set of levels in a hierarchy. A variety of hierarchical waveforms may be generated with a signal generator as disclosed herein. For example, the pulse waveform may include a first level of a hierarchy of the pulse waveform including a first set of pulses. Each pulse has a pulse time duration and a first time interval separating successive pulses. A second level of the hierarchy of the pulse waveform may include a plurality of first sets of pulses as a second set of pulses. A second time interval may separate successive first sets of pulses. The second time interval may be at least three times the duration of the first time interval. A third level of the hierarchy of the pulse waveform may include a plurality of second sets of pulses as a third set of pulses. A third time interval may separate successive second sets of pulses. The third time interval may be at least thirty times the duration of the second level time interval.
It is understood that while the examples herein identify separate monophasic and biphasic waveforms, it should be appreciated that combination waveforms, where some portions of the waveform hierarchy are monophasic while other portions are biphasic, may also be generated. A voltage pulse waveform having a hierarchical structure may be applied across different anode-cathode subsets (optionally with a time delay). As discussed above, one or more of the waveforms applied across the anode-cathode subsets may be applied during the refractory period of a cardiac cycle. The generated pulse waveform may be delivered to tissue. Accordingly, in the embodiments described herein, a contiguous, transmural zone of ablated tissue may be generated to electrically isolate the pulmonary vein from a main body of the left atrium.
In some embodiments, the pulse waveform may be delivered to pulmonary vein of a heart of a patient via one or more electrodes of a set of jaws of an ablation device. In other embodiments, voltage pulse waveforms as described herein may be selectively delivered to electrode subsets such as paired anode-cathode subsets for ablation and isolation of the pulmonary vein. For example, a first electrode of a first jaw may be configured as an anode and a second electrode of a second jaw may be configured as a cathode. These steps may be repeated for a desired number of pulmonary vein regions to be ablated.
In some embodiments, the electrodes configured to deliver energy to tissue (260) may be adjacent electrodes on the same jaw. For example, a first electrode (210) may be configured as an anode and a second electrode (220) may be configured as a cathode. In
In some embodiments, the electrodes configured to deliver energy to tissue (360) may be adjacent electrodes on the same jaw. For example, a first electrode (310) may be configured as an anode and a second electrode (320) may be configured as a cathode. In
In some embodiments, the electrodes configured to deliver energy to tissue (460) may be electrodes that directly oppose each other on different jaws within the cross-section orthogonal to the longitudinal axis. For example, a second electrode (420) may be configured as an anode and a fourth electrode (440) may be configured as a cathode. In
In some embodiments, the electrodes configured to deliver energy to tissue (560) may be electrodes that are laterally spaced apart and adjacent on opposing different jaws. For example, a second electrode (520) may be configured as an anode and a third electrode (530) may be configured as a cathode. This anode-cathode configuration of the electrodes reduces the risk of electrical shorting since the anode and cathode will not contact each other even if the jaws are brought into contact with each other. In
Disclosed herein are methods, systems and apparatuses for the selective and rapid application of pulsed electric fields/waveforms to effect tissue ablation with irreversible electroporation. The pulse waveform(s) as disclosed herein are usable with any of the systems (600), devices (e.g., 200, 300, 400, 500, 640, 700, 800, 900, 1000), and methods (e.g., 1100) described herein. Some embodiments are directed to pulsed high voltage waveforms together with a sequenced delivery scheme for delivering energy to tissue via sets of electrodes. In some embodiments, peak electric field values may be reduced and/or minimized while at the same time sufficiently large electric field magnitudes may be maintained in regions where tissue ablation is desired. This also reduces the likelihood of excessive tissue damage or the generation of electrical arcing, and locally high temperature increases. In some embodiments, a system useful for irreversible electroporation includes a signal generator and a processor capable of being configured to apply pulsed voltage waveforms to a selected plurality or a subset of electrodes of an ablation device. In some embodiments, the processor is configured to control inputs whereby selected pairs of anode-cathode subsets of electrodes may be sequentially triggered based on a pre-determined sequence, and in one embodiment the sequenced delivery may be triggered from a cardiac stimulator and/or pacing device. In some embodiments, the ablation pulse waveforms are applied in a refractory period of the cardiac cycle to avoid disruption of the sinus rhythm of the heart. One example method of enforcing this is to electrically pace the heart with a cardiac stimulator and ensure pacing capture to establish periodicity and predictability of the cardiac cycle, and then to define a time window well within the refractory period of this periodic cycle within which the ablation waveform is delivered.
In some embodiments, the pulsed voltage waveforms disclosed herein are hierarchical in organization and have a nested structure. In some embodiments, the pulsed waveform includes hierarchical groupings of pulses with a variety of associated timescales. Furthermore, the associated timescales and pulse widths, and the numbers of pulses and hierarchical groupings, may be selected to satisfy one or more of a set of Diophantine inequalities involving the frequency of cardiac pacing.
Pulsed waveforms for electroporation energy delivery as disclosed herein may enhance the safety, efficiency and effectiveness of the energy delivery by reducing the electric field threshold associated with irreversible electroporation, yielding more effective ablative lesions with reduced total energy delivered. This in turn may broaden the areas of clinical application of electroporation including therapeutic treatment of a variety of cardiac arrhythmias.
Embodiments disclosed herein include waveforms structured as hierarchical waveforms that include waveform elements/pulses at various levels of the hierarchy. The individual pulses such as (1300) in
In some embodiments, hierarchical waveforms with a nested structure and hierarchy of time intervals as described herein are useful for irreversible electroporation ablation energy delivery, providing a good degree of control and selectivity for applications in different tissue types. A variety of hierarchical waveforms may be generated with a suitable pulse generator. It is understood that while the examples herein identify separate monophasic and biphasic waveforms for clarity, it should be noted that combination waveforms, where some portions of the waveform hierarchy are monophasic while other portions are biphasic, may also be generated/implemented.
In some embodiments, the ablation pulse waveforms described herein are applied during the refractory period of the cardiac cycle to avoid disruption of the sinus rhythm of the heart. In some embodiments, a method of treatment includes electrically pacing the heart with a cardiac stimulator to ensure pacing capture to establish periodicity and predictability of the cardiac cycle, and then defining a time window within the refractory period of the cardiac cycle within which one or more pulsed ablation waveforms may be delivered.
It should be understood that the examples and illustrations in this disclosure serve exemplary purposes and departures and variations such as the shape and size of the jaws and electrodes, number of electrodes, and so on may be built and deployed according to the teachings herein without departing from the scope of this invention.
As used herein, the terms “about” and/or “approximately” when used in conjunction with numerical values and/or ranges generally refer to those numerical values and/or ranges near to a recited numerical value and/or range. In some instances, the terms “about” and “approximately” may mean within ±10% of the recited value. For example, in some instances, “about 100 [units]” may mean within ±10% of 100 (e.g., from 90 to 110). The terms “about” and “approximately” may be used interchangeably.
Some embodiments described herein relate to a computer storage product with a non-transitory computer-readable medium (also may be referred to as a non-transitory processor-readable medium) having instructions or computer code thereon for performing various computer-implemented operations. The computer-readable medium (or processor-readable medium) is non-transitory in the sense that it does not include transitory propagating signals per se (e.g., a propagating electromagnetic wave carrying information on a transmission medium such as space or a cable). The media and computer code (also may be referred to as code or algorithm) may be those designed and constructed for the specific purpose or purposes. Examples of non-transitory computer-readable media include, but are not limited to, magnetic storage media such as hard disks, floppy disks, and magnetic tape; optical storage media such as Compact Disc/Digital Video Discs (CD/DVDs), Compact Disc-Read Only Memories (CD-ROMs), and holographic devices; magneto-optical storage media such as optical disks; carrier wave signal processing modules; and hardware devices that are specially configured to store and execute program code, such as Application-Specific Integrated Circuits (ASICs), Programmable Logic Devices (PLDs), Read-Only Memory (ROM) and Random-Access Memory (RAM) devices. Other embodiments described herein relate to a computer program product, which may include, for example, the instructions and/or computer code disclosed herein.
The systems, devices, and/or methods described herein may be performed by software (executed on hardware), hardware, or a combination thereof. Hardware modules may include, for example, a general-purpose processor (or microprocessor or microcontroller), a field programmable gate array (FPGA), and/or an application specific integrated circuit (ASIC). Software modules (executed on hardware) may be expressed in a variety of software languages (e.g., computer code), including C, C++, Java®, Ruby, Visual Basic®, and/or other object-oriented, procedural, or other programming language and development tools. Examples of computer code include, but are not limited to, micro-code or micro-instructions, machine instructions, such as produced by a compiler, code used to produce a web service, and files containing higher-level instructions that are executed by a computer using an interpreter. Additional examples of computer code include, but are not limited to, control signals, encrypted code, and compressed code.
The specific examples and descriptions herein are exemplary in nature and embodiments may be developed by those skilled in the art based on the material taught herein without departing from the scope of the present invention, which is limited only by the attached claims.
This application is a continuation of International Application No. PCT/US2019/028943, filed on Apr. 24, 2019, which claims the benefit of and is a continuation of U.S. application Ser. No. 15/970,404, filed on May 3, 2018, now abandoned, the entire disclosure of each of which is incorporated herein by reference in its entirety.
| Number | Name | Date | Kind |
|---|---|---|---|
| 4200104 | Harris | Apr 1980 | A |
| 4470407 | Hussein | Sep 1984 | A |
| 4739759 | Rexroth et al. | Apr 1988 | A |
| 5234004 | Hascoet et al. | Aug 1993 | A |
| 5242441 | Avitall | Sep 1993 | A |
| 5257635 | Langberg | Nov 1993 | A |
| 5281213 | Milder et al. | Jan 1994 | A |
| 5304214 | DeFord et al. | Apr 1994 | A |
| 5306296 | Wright et al. | Apr 1994 | A |
| 5334193 | Nardella | Aug 1994 | A |
| 5341807 | Nardella | Aug 1994 | A |
| 5342301 | Saab | Aug 1994 | A |
| 5398683 | Edwards et al. | Mar 1995 | A |
| 5443463 | Stern et al. | Aug 1995 | A |
| 5454370 | Avitall | Oct 1995 | A |
| 5515848 | Corbett, III et al. | May 1996 | A |
| 5531685 | Hemmer et al. | Jul 1996 | A |
| 5545161 | Imran | Aug 1996 | A |
| 5578040 | Smith | Nov 1996 | A |
| 5617854 | Munsif | Apr 1997 | A |
| 5624430 | Eton et al. | Apr 1997 | A |
| 5667491 | Pliquett et al. | Sep 1997 | A |
| 5672170 | Cho | Sep 1997 | A |
| 5700243 | Narciso, Jr. | Dec 1997 | A |
| 5702438 | Avitall | Dec 1997 | A |
| 5706823 | Wodlinger | Jan 1998 | A |
| 5722400 | Ockuly et al. | Mar 1998 | A |
| 5722402 | Swanson et al. | Mar 1998 | A |
| 5749914 | Janssen | May 1998 | A |
| 5779699 | Lipson | Jul 1998 | A |
| 5788692 | Campbell et al. | Aug 1998 | A |
| 5810762 | Hofmann | Sep 1998 | A |
| 5833710 | Jacobson | Nov 1998 | A |
| 5836874 | Swanson et al. | Nov 1998 | A |
| 5836942 | Netherly et al. | Nov 1998 | A |
| 5836947 | Fleischman et al. | Nov 1998 | A |
| 5843154 | Osypka | Dec 1998 | A |
| 5849028 | Chen | Dec 1998 | A |
| 5863291 | Schaer | Jan 1999 | A |
| 5868736 | Swanson et al. | Feb 1999 | A |
| 5871523 | Fleischman et al. | Feb 1999 | A |
| 5876336 | Swanson et al. | Mar 1999 | A |
| 5885278 | Fleischman et al. | Mar 1999 | A |
| 5895404 | Ruiz | Apr 1999 | A |
| 5899917 | Edwards et al. | May 1999 | A |
| 5904709 | Arndt et al. | May 1999 | A |
| 5913854 | Maguire et al. | Jun 1999 | A |
| 5916158 | Webster, Jr. | Jun 1999 | A |
| 5916213 | Haissaguerre et al. | Jun 1999 | A |
| 5921924 | Avitall | Jul 1999 | A |
| 5928269 | Alt | Jul 1999 | A |
| 5928270 | Ramsey, III | Jul 1999 | A |
| 6002955 | Willems et al. | Dec 1999 | A |
| 6006131 | Cooper et al. | Dec 1999 | A |
| 6009351 | Flachman | Dec 1999 | A |
| 6014579 | Pomeranz et al. | Jan 2000 | A |
| 6029671 | Stevens et al. | Feb 2000 | A |
| 6033403 | Tu et al. | Mar 2000 | A |
| 6035238 | Ingle et al. | Mar 2000 | A |
| 6045550 | Simpson et al. | Apr 2000 | A |
| 6068653 | LaFontaine | May 2000 | A |
| 6071274 | Thompson et al. | Jun 2000 | A |
| 6071281 | Burnside et al. | Jun 2000 | A |
| 6074389 | Levine et al. | Jun 2000 | A |
| 6076012 | Swanson et al. | Jun 2000 | A |
| 6090104 | Webster, Jr. | Jul 2000 | A |
| 6096036 | Bowe et al. | Aug 2000 | A |
| 6113595 | Muntermann | Sep 2000 | A |
| 6119041 | Pomeranz et al. | Sep 2000 | A |
| 6120500 | Bednarek et al. | Sep 2000 | A |
| 6146381 | Bowe et al. | Nov 2000 | A |
| 6164283 | Lesh | Dec 2000 | A |
| 6167291 | Barajas et al. | Dec 2000 | A |
| 6171305 | Sherman | Jan 2001 | B1 |
| 6216034 | Hofmann et al. | Apr 2001 | B1 |
| 6219582 | Hofstad et al. | Apr 2001 | B1 |
| 6223085 | Dann et al. | Apr 2001 | B1 |
| 6231518 | Grabek et al. | May 2001 | B1 |
| 6245064 | Lesh et al. | Jun 2001 | B1 |
| 6251107 | Schaer | Jun 2001 | B1 |
| 6251128 | Knopp et al. | Jun 2001 | B1 |
| 6270476 | Santoianni et al. | Aug 2001 | B1 |
| 6272384 | Simon et al. | Aug 2001 | B1 |
| 6287306 | Kroll et al. | Sep 2001 | B1 |
| 6314963 | Vaska et al. | Nov 2001 | B1 |
| 6322559 | Daulton et al. | Nov 2001 | B1 |
| 6350263 | Wetzig et al. | Feb 2002 | B1 |
| 6370412 | Armoundas et al. | Apr 2002 | B1 |
| 6391024 | Sun et al. | May 2002 | B1 |
| 6447505 | McGovern et al. | Sep 2002 | B2 |
| 6464699 | Swanson | Oct 2002 | B1 |
| 6470211 | Ideker et al. | Oct 2002 | B1 |
| 6502576 | Lesh | Jan 2003 | B1 |
| 6503247 | Swartz et al. | Jan 2003 | B2 |
| 6517534 | McGovern et al. | Feb 2003 | B1 |
| 6527724 | Fenici | Mar 2003 | B1 |
| 6527767 | Wang et al. | Mar 2003 | B2 |
| 6592581 | Bowe | Jul 2003 | B2 |
| 6595991 | Tollner et al. | Jul 2003 | B2 |
| 6607520 | Keane | Aug 2003 | B2 |
| 6623480 | Kuo et al. | Sep 2003 | B1 |
| 6638278 | Falwell et al. | Oct 2003 | B2 |
| 6666863 | Wentzel et al. | Dec 2003 | B2 |
| 6669693 | Friedman | Dec 2003 | B2 |
| 6702811 | Stewart et al. | Mar 2004 | B2 |
| 6719756 | Muntermann | Apr 2004 | B1 |
| 6723092 | Brown et al. | Apr 2004 | B2 |
| 6728563 | Rashidi | Apr 2004 | B2 |
| 6743225 | Sanchez et al. | Jun 2004 | B2 |
| 6743226 | Cosman et al. | Jun 2004 | B2 |
| 6743239 | Kuehn et al. | Jun 2004 | B1 |
| 6764486 | Natale | Jul 2004 | B2 |
| 6780181 | Kroll et al. | Aug 2004 | B2 |
| 6805128 | Pless | Oct 2004 | B1 |
| 6807447 | Griffin, III | Oct 2004 | B2 |
| 6892091 | Ben-Haim et al. | May 2005 | B1 |
| 6893438 | Hall et al. | May 2005 | B2 |
| 6926714 | Sra | Aug 2005 | B1 |
| 6955173 | Lesh | Oct 2005 | B2 |
| 6960206 | Keane | Nov 2005 | B2 |
| 6960207 | Vanney et al. | Nov 2005 | B2 |
| 6972016 | Hill, III et al. | Dec 2005 | B2 |
| 6973339 | Govari | Dec 2005 | B2 |
| 6979331 | Hintringer et al. | Dec 2005 | B2 |
| 6984232 | Vanney et al. | Jan 2006 | B2 |
| 6985776 | Kane et al. | Jan 2006 | B2 |
| 7001383 | Keidar | Feb 2006 | B2 |
| 7041095 | Wang et al. | May 2006 | B2 |
| 7113831 | Hooven | Sep 2006 | B2 |
| 7171263 | Darvish et al. | Jan 2007 | B2 |
| 7182725 | Bonan et al. | Feb 2007 | B2 |
| 7195628 | Falkenberg | Mar 2007 | B2 |
| 7207988 | Leckrone et al. | Apr 2007 | B2 |
| 7207989 | Pike, Jr. et al. | Apr 2007 | B2 |
| 7229402 | Diaz et al. | Jun 2007 | B2 |
| 7229437 | Johnson et al. | Jun 2007 | B2 |
| 7250049 | Roop et al. | Jul 2007 | B2 |
| 7285116 | de la Rama et al. | Oct 2007 | B2 |
| 7285119 | Stewart et al. | Oct 2007 | B2 |
| 7326208 | Vanney et al. | Feb 2008 | B2 |
| 7346379 | Eng et al. | Mar 2008 | B2 |
| 7367974 | Haemmerich et al. | May 2008 | B2 |
| 7374567 | Heuser | May 2008 | B2 |
| 7387629 | Vanney et al. | Jun 2008 | B2 |
| 7387630 | Mest | Jun 2008 | B2 |
| 7387636 | Cohn et al. | Jun 2008 | B2 |
| 7416552 | Paul et al. | Aug 2008 | B2 |
| 7419477 | Simpson et al. | Sep 2008 | B2 |
| 7419489 | Vanney et al. | Sep 2008 | B2 |
| 7422591 | Phan | Sep 2008 | B2 |
| 7429261 | Kunis et al. | Sep 2008 | B2 |
| 7435248 | Taimisto et al. | Oct 2008 | B2 |
| 7513896 | Orszulak | Apr 2009 | B2 |
| 7527625 | Knight et al. | May 2009 | B2 |
| 7578816 | Boveja et al. | Aug 2009 | B2 |
| 7588567 | Boveja et al. | Sep 2009 | B2 |
| 7623899 | Worley et al. | Nov 2009 | B2 |
| 7678108 | Chrisitian et al. | Mar 2010 | B2 |
| 7681579 | Schwartz | Mar 2010 | B2 |
| 7771421 | Stewart et al. | Aug 2010 | B2 |
| 7805182 | Weese et al. | Sep 2010 | B2 |
| 7850642 | Moll et al. | Dec 2010 | B2 |
| 7850685 | Kunis et al. | Dec 2010 | B2 |
| 7857808 | Oral et al. | Dec 2010 | B2 |
| 7857809 | Drysen | Dec 2010 | B2 |
| 7869865 | Govari et al. | Jan 2011 | B2 |
| 7896873 | Hiller et al. | Mar 2011 | B2 |
| 7917211 | Zacouto | Mar 2011 | B2 |
| 7918819 | Karmarkar et al. | Apr 2011 | B2 |
| 7918850 | Govari et al. | Apr 2011 | B2 |
| 7922714 | Stevens-Wright | Apr 2011 | B2 |
| 7955827 | Rubinsky et al. | Jun 2011 | B2 |
| 8048067 | Davalos et al. | Nov 2011 | B2 |
| 8048072 | Verin et al. | Nov 2011 | B2 |
| 8100895 | Panos et al. | Jan 2012 | B2 |
| 8100900 | Prinz et al. | Jan 2012 | B2 |
| 8108069 | Stahler et al. | Jan 2012 | B2 |
| 8133220 | Lee et al. | Mar 2012 | B2 |
| 8137342 | Crossman | Mar 2012 | B2 |
| 8145289 | Calabro′ et al. | Mar 2012 | B2 |
| 8147486 | Honour et al. | Apr 2012 | B2 |
| 8160690 | Wilfley et al. | Apr 2012 | B2 |
| 8175680 | Panescu | May 2012 | B2 |
| 8182477 | Orszulak et al. | May 2012 | B2 |
| 8206384 | Falwell et al. | Jun 2012 | B2 |
| 8206385 | Stangenes et al. | Jun 2012 | B2 |
| 8216221 | Ibrahim et al. | Jul 2012 | B2 |
| 8221411 | Francischelli et al. | Jul 2012 | B2 |
| 8226648 | Paul et al. | Jul 2012 | B2 |
| 8228065 | Wirtz et al. | Jul 2012 | B2 |
| 8235986 | Kulesa et al. | Aug 2012 | B2 |
| 8235988 | Davis et al. | Aug 2012 | B2 |
| 8251986 | Chornenky et al. | Aug 2012 | B2 |
| 8282631 | Davalos et al. | Oct 2012 | B2 |
| 8287532 | Carroll et al. | Oct 2012 | B2 |
| 8414508 | Thapliyal et al. | Apr 2013 | B2 |
| 8430875 | Ibrahim et al. | Apr 2013 | B2 |
| 8433394 | Harlev et al. | Apr 2013 | B2 |
| 8449535 | Deno et al. | May 2013 | B2 |
| 8454594 | Demarais et al. | Jun 2013 | B2 |
| 8463368 | Harlev et al. | Jun 2013 | B2 |
| 8475450 | Govari et al. | Jul 2013 | B2 |
| 8486063 | Werneth et al. | Jul 2013 | B2 |
| 8500733 | Watson | Aug 2013 | B2 |
| 8535304 | Sklar et al. | Sep 2013 | B2 |
| 8538501 | Venkatachalam et al. | Sep 2013 | B2 |
| 8562588 | Hobbs et al. | Oct 2013 | B2 |
| 8568406 | Harlev et al. | Oct 2013 | B2 |
| 8568410 | Vakharia et al. | Oct 2013 | B2 |
| 8571635 | McGee | Oct 2013 | B2 |
| 8571647 | Harlev et al. | Oct 2013 | B2 |
| 8579897 | Vakharia et al. | Nov 2013 | B2 |
| 8585695 | Shih | Nov 2013 | B2 |
| 8588885 | Hall et al. | Nov 2013 | B2 |
| 8597288 | Christian | Dec 2013 | B2 |
| 8608735 | Govari et al. | Dec 2013 | B2 |
| 8628522 | Ibrahim et al. | Jan 2014 | B2 |
| 8632534 | Pearson et al. | Jan 2014 | B2 |
| 8647338 | Chornenky et al. | Feb 2014 | B2 |
| 8708952 | Cohen et al. | Apr 2014 | B2 |
| 8734442 | Cao et al. | May 2014 | B2 |
| 8771267 | Kunis et al. | Jul 2014 | B2 |
| 8795310 | Fung et al. | Aug 2014 | B2 |
| 8808273 | Caples et al. | Aug 2014 | B2 |
| 8808281 | Emons et al. | Aug 2014 | B2 |
| 8834461 | Werneth et al. | Sep 2014 | B2 |
| 8834464 | Stewart et al. | Sep 2014 | B2 |
| 8868169 | Narayan et al. | Oct 2014 | B2 |
| 8876817 | Avitall et al. | Nov 2014 | B2 |
| 8880195 | Azure | Nov 2014 | B2 |
| 8886309 | Luther et al. | Nov 2014 | B2 |
| 8903488 | Callas et al. | Dec 2014 | B2 |
| 8920411 | Gelbart et al. | Dec 2014 | B2 |
| 8926589 | Govari | Jan 2015 | B2 |
| 8932287 | Gelbart et al. | Jan 2015 | B2 |
| 8945117 | Bencini | Feb 2015 | B2 |
| 8979841 | Kunis et al. | Mar 2015 | B2 |
| 8986278 | Fung et al. | Mar 2015 | B2 |
| 9002442 | Harley et al. | Apr 2015 | B2 |
| 9005189 | Davalos et al. | Apr 2015 | B2 |
| 9005194 | Oral et al. | Apr 2015 | B2 |
| 9011425 | Fischer et al. | Apr 2015 | B2 |
| 9044245 | Condie et al. | Jun 2015 | B2 |
| 9055959 | Vaska et al. | Jun 2015 | B2 |
| 9072518 | Swanson | Jul 2015 | B2 |
| 9078667 | Besser et al. | Jul 2015 | B2 |
| 9101374 | Hoch et al. | Aug 2015 | B1 |
| 9119533 | Ghaffari | Sep 2015 | B2 |
| 9119634 | Gelbart et al. | Sep 2015 | B2 |
| 9131897 | Harada et al. | Sep 2015 | B2 |
| 9155590 | Mathur | Oct 2015 | B2 |
| 9162037 | Belson et al. | Oct 2015 | B2 |
| 9179972 | Olson | Nov 2015 | B2 |
| 9186481 | Avitall et al. | Nov 2015 | B2 |
| 9192769 | Donofrio et al. | Nov 2015 | B2 |
| 9211405 | Mahapatra et al. | Dec 2015 | B2 |
| 9216055 | Spence et al. | Dec 2015 | B2 |
| 9233248 | Luther et al. | Jan 2016 | B2 |
| 9237926 | Nollert et al. | Jan 2016 | B2 |
| 9262252 | Kirkpatrick et al. | Feb 2016 | B2 |
| 9277957 | Long et al. | Mar 2016 | B2 |
| 9282910 | Narayan et al. | Mar 2016 | B2 |
| 9289258 | Cohen | Mar 2016 | B2 |
| 9289606 | Paul et al. | Mar 2016 | B2 |
| 9295516 | Pearson et al. | Mar 2016 | B2 |
| 9301801 | Scheib | Apr 2016 | B2 |
| 9375268 | Long | Jun 2016 | B2 |
| 9414881 | Callas et al. | Aug 2016 | B2 |
| 9468495 | Kunis et al. | Oct 2016 | B2 |
| 9474486 | Eliason et al. | Oct 2016 | B2 |
| 9474574 | Ibrahim et al. | Oct 2016 | B2 |
| 9480525 | Lopes et al. | Nov 2016 | B2 |
| 9486272 | Bonyak et al. | Nov 2016 | B2 |
| 9486273 | Lopes et al. | Nov 2016 | B2 |
| 9492227 | Lopes et al. | Nov 2016 | B2 |
| 9492228 | Lopes et al. | Nov 2016 | B2 |
| 9517103 | Panescu et al. | Dec 2016 | B2 |
| 9526573 | Lopes et al. | Dec 2016 | B2 |
| 9532831 | Reinders et al. | Jan 2017 | B2 |
| 9539010 | Gagner et al. | Jan 2017 | B2 |
| 9554848 | Stewart et al. | Jan 2017 | B2 |
| 9554851 | Sklar et al. | Jan 2017 | B2 |
| 9610118 | Olson | Apr 2017 | B2 |
| 9700368 | Callas et al. | Jul 2017 | B2 |
| 9724170 | Mickelsen | Aug 2017 | B2 |
| 9757193 | Zarins et al. | Sep 2017 | B2 |
| 9782099 | Williams et al. | Oct 2017 | B2 |
| 9795442 | Salahieh et al. | Oct 2017 | B2 |
| 9861802 | Mickelsen | Jan 2018 | B2 |
| 9913685 | Clark et al. | Mar 2018 | B2 |
| 9931487 | Quinn et al. | Apr 2018 | B2 |
| 9987081 | Bowers et al. | Jun 2018 | B1 |
| 9999465 | Long et al. | Jun 2018 | B2 |
| 10016232 | Bowers et al. | Jul 2018 | B1 |
| 10130423 | Viswanathan et al. | Nov 2018 | B1 |
| 10172673 | Viswanathan et al. | Jan 2019 | B2 |
| 10322286 | Viswanathan et al. | Jun 2019 | B2 |
| 10433906 | Mickelsen | Oct 2019 | B2 |
| 10433908 | Viswanathan et al. | Oct 2019 | B2 |
| 10507302 | Leeflang et al. | Dec 2019 | B2 |
| 10512505 | Viswanathan | Dec 2019 | B2 |
| 10512779 | Viswanathan et al. | Dec 2019 | B2 |
| 10517672 | Long | Dec 2019 | B2 |
| 10624693 | Mickelsen et al. | Apr 2020 | B2 |
| 10835314 | Long et al. | Nov 2020 | B2 |
| 11020180 | Viswanathan et al. | Jun 2021 | B2 |
| 20010000791 | Suorsa et al. | May 2001 | A1 |
| 20010007070 | Stewart et al. | Jul 2001 | A1 |
| 20010044624 | Seraj et al. | Nov 2001 | A1 |
| 20020052602 | Wang et al. | May 2002 | A1 |
| 20020077627 | Johnson et al. | Jun 2002 | A1 |
| 20020087169 | Brock et al. | Jul 2002 | A1 |
| 20020091384 | Hooven et al. | Jul 2002 | A1 |
| 20020095176 | Liddicoat et al. | Jul 2002 | A1 |
| 20020111618 | Stewart et al. | Aug 2002 | A1 |
| 20020156526 | Hlavka et al. | Oct 2002 | A1 |
| 20020161323 | Miller et al. | Oct 2002 | A1 |
| 20020169445 | Jain et al. | Nov 2002 | A1 |
| 20020177765 | Bowe et al. | Nov 2002 | A1 |
| 20020183638 | Swanson | Dec 2002 | A1 |
| 20030014098 | Quijano et al. | Jan 2003 | A1 |
| 20030018374 | Paulos | Jan 2003 | A1 |
| 20030023287 | Edwards et al. | Jan 2003 | A1 |
| 20030028189 | Woloszko et al. | Feb 2003 | A1 |
| 20030050637 | Maguire et al. | Mar 2003 | A1 |
| 20030114849 | Ryan | Jun 2003 | A1 |
| 20030125729 | Hooven et al. | Jul 2003 | A1 |
| 20030130598 | Manning et al. | Jul 2003 | A1 |
| 20030130711 | Pearson et al. | Jul 2003 | A1 |
| 20030204161 | Ferek Petric | Oct 2003 | A1 |
| 20030229379 | Ramsey | Dec 2003 | A1 |
| 20040039382 | Kroll et al. | Feb 2004 | A1 |
| 20040049181 | Stewart et al. | Mar 2004 | A1 |
| 20040049182 | Koblish et al. | Mar 2004 | A1 |
| 20040082859 | Schaer | Apr 2004 | A1 |
| 20040082948 | Stewart et al. | Apr 2004 | A1 |
| 20040087939 | Eggers et al. | May 2004 | A1 |
| 20040111087 | Stern et al. | Jun 2004 | A1 |
| 20040199157 | Palanker et al. | Oct 2004 | A1 |
| 20040215139 | Cohen | Oct 2004 | A1 |
| 20040231683 | Eng et al. | Nov 2004 | A1 |
| 20040236360 | Cohn et al. | Nov 2004 | A1 |
| 20040254607 | Wittenberger et al. | Dec 2004 | A1 |
| 20040267337 | Hayzelden | Dec 2004 | A1 |
| 20050033282 | Hooven | Feb 2005 | A1 |
| 20050187545 | Hooven et al. | Aug 2005 | A1 |
| 20050222632 | Obino | Oct 2005 | A1 |
| 20050251130 | Boveja et al. | Nov 2005 | A1 |
| 20050261672 | Deem et al. | Nov 2005 | A1 |
| 20060009755 | Sra | Jan 2006 | A1 |
| 20060009759 | Chrisitian et al. | Jan 2006 | A1 |
| 20060015095 | Desinger et al. | Jan 2006 | A1 |
| 20060015165 | Bertolero et al. | Jan 2006 | A1 |
| 20060024359 | Walker et al. | Feb 2006 | A1 |
| 20060058781 | Long | Mar 2006 | A1 |
| 20060111702 | Oral et al. | May 2006 | A1 |
| 20060142801 | Demarais et al. | Jun 2006 | A1 |
| 20060167448 | Kozel | Jul 2006 | A1 |
| 20060217703 | Chornenky et al. | Sep 2006 | A1 |
| 20060241734 | Marshall et al. | Oct 2006 | A1 |
| 20060264752 | Rubinsky et al. | Nov 2006 | A1 |
| 20060270900 | Chin et al. | Nov 2006 | A1 |
| 20060287648 | Schwartz | Dec 2006 | A1 |
| 20060293730 | Rubinsky et al. | Dec 2006 | A1 |
| 20060293731 | Rubinsky et al. | Dec 2006 | A1 |
| 20070005053 | Dando | Jan 2007 | A1 |
| 20070021744 | Creighton | Jan 2007 | A1 |
| 20070060989 | Deem et al. | Mar 2007 | A1 |
| 20070066972 | Ormsby et al. | Mar 2007 | A1 |
| 20070129721 | Phan et al. | Jun 2007 | A1 |
| 20070129760 | Demarais et al. | Jun 2007 | A1 |
| 20070156135 | Rubinsky et al. | Jul 2007 | A1 |
| 20070167740 | Grunewald et al. | Jul 2007 | A1 |
| 20070167940 | Stevens-Wright | Jul 2007 | A1 |
| 20070173878 | Heuser | Jul 2007 | A1 |
| 20070191826 | Park | Aug 2007 | A1 |
| 20070208329 | Ward et al. | Sep 2007 | A1 |
| 20070225589 | Viswanathan | Sep 2007 | A1 |
| 20070249923 | Keenan | Oct 2007 | A1 |
| 20070260223 | Scheibe et al. | Nov 2007 | A1 |
| 20070270792 | Hennemann et al. | Nov 2007 | A1 |
| 20080009855 | Hamou | Jan 2008 | A1 |
| 20080033426 | Machell | Feb 2008 | A1 |
| 20080065061 | Viswanathan | Mar 2008 | A1 |
| 20080086120 | Mirza et al. | Apr 2008 | A1 |
| 20080091195 | Silwa et al. | Apr 2008 | A1 |
| 20080103545 | Bolea et al. | May 2008 | A1 |
| 20080132885 | Rubinsky et al. | Jun 2008 | A1 |
| 20080161789 | Thao et al. | Jul 2008 | A1 |
| 20080172048 | Martin et al. | Jul 2008 | A1 |
| 20080200913 | Viswanathan | Aug 2008 | A1 |
| 20080208118 | Goldman | Aug 2008 | A1 |
| 20080243214 | Koblish | Oct 2008 | A1 |
| 20080281322 | Sherman et al. | Nov 2008 | A1 |
| 20080300574 | Belson et al. | Dec 2008 | A1 |
| 20080300588 | Groth et al. | Dec 2008 | A1 |
| 20090024084 | Khosla et al. | Jan 2009 | A1 |
| 20090048591 | Ibrahim et al. | Feb 2009 | A1 |
| 20090062788 | Long et al. | Mar 2009 | A1 |
| 20090062792 | Vakharia et al. | Mar 2009 | A1 |
| 20090076500 | Azure | Mar 2009 | A1 |
| 20090105654 | Kurth et al. | Apr 2009 | A1 |
| 20090138009 | Viswanathan et al. | May 2009 | A1 |
| 20090149917 | Whitehurst et al. | Jun 2009 | A1 |
| 20090163905 | Winkler et al. | Jun 2009 | A1 |
| 20090228003 | Sinelnikov | Sep 2009 | A1 |
| 20090240248 | Deford et al. | Sep 2009 | A1 |
| 20090275827 | Aiken et al. | Nov 2009 | A1 |
| 20090281477 | Mikus et al. | Nov 2009 | A1 |
| 20090306651 | Schneider | Dec 2009 | A1 |
| 20100004623 | Hamilton et al. | Jan 2010 | A1 |
| 20100023004 | Francischelli et al. | Jan 2010 | A1 |
| 20100137861 | Soroff et al. | Jun 2010 | A1 |
| 20100185140 | Kassab et al. | Jul 2010 | A1 |
| 20100185186 | Longoria | Jul 2010 | A1 |
| 20100191112 | Demarais et al. | Jul 2010 | A1 |
| 20100191232 | Boveda | Jul 2010 | A1 |
| 20100241185 | Mahapatra et al. | Sep 2010 | A1 |
| 20100261994 | Davalos et al. | Oct 2010 | A1 |
| 20100274238 | Klimovitch | Oct 2010 | A1 |
| 20100280513 | Juergen et al. | Nov 2010 | A1 |
| 20100280539 | Miyoshi et al. | Nov 2010 | A1 |
| 20100292687 | Kauphusman et al. | Nov 2010 | A1 |
| 20100312096 | Guttman et al. | Dec 2010 | A1 |
| 20100312300 | Ryu et al. | Dec 2010 | A1 |
| 20100331838 | Ibrahim | Dec 2010 | A1 |
| 20110028962 | Werneth et al. | Feb 2011 | A1 |
| 20110028964 | Edwards | Feb 2011 | A1 |
| 20110040199 | Hopenfeld | Feb 2011 | A1 |
| 20110098694 | Long | Apr 2011 | A1 |
| 20110106221 | Neal, II et al. | May 2011 | A1 |
| 20110130708 | Perry et al. | Jun 2011 | A1 |
| 20110144524 | Fish et al. | Jun 2011 | A1 |
| 20110144633 | Govari | Jun 2011 | A1 |
| 20110160785 | Mori et al. | Jun 2011 | A1 |
| 20110190659 | Long et al. | Aug 2011 | A1 |
| 20110190727 | Edmunds et al. | Aug 2011 | A1 |
| 20110208185 | Diamant et al. | Aug 2011 | A1 |
| 20110213231 | Hall et al. | Sep 2011 | A1 |
| 20110276047 | Sklar et al. | Nov 2011 | A1 |
| 20110276075 | Fung et al. | Nov 2011 | A1 |
| 20110288544 | Verin et al. | Nov 2011 | A1 |
| 20110288547 | Morgan et al. | Nov 2011 | A1 |
| 20110313417 | De La Rama et al. | Dec 2011 | A1 |
| 20120029512 | Willard et al. | Feb 2012 | A1 |
| 20120046570 | Villegas et al. | Feb 2012 | A1 |
| 20120053581 | Wittkampf et al. | Mar 2012 | A1 |
| 20120059255 | Paul et al. | Mar 2012 | A1 |
| 20120071872 | Rubinsky et al. | Mar 2012 | A1 |
| 20120078320 | Schotzko et al. | Mar 2012 | A1 |
| 20120078343 | Fish | Mar 2012 | A1 |
| 20120089089 | Swain et al. | Apr 2012 | A1 |
| 20120095459 | Callas et al. | Apr 2012 | A1 |
| 20120101413 | Beetel et al. | Apr 2012 | A1 |
| 20120158021 | Morrill | Jun 2012 | A1 |
| 20120165667 | Altmann et al. | Jun 2012 | A1 |
| 20120172859 | Condie et al. | Jul 2012 | A1 |
| 20120172867 | Ryu et al. | Jul 2012 | A1 |
| 20120197100 | Razavi et al. | Aug 2012 | A1 |
| 20120209260 | Lambert et al. | Aug 2012 | A1 |
| 20120220998 | Long et al. | Aug 2012 | A1 |
| 20120265198 | Crow et al. | Oct 2012 | A1 |
| 20120283582 | Mahapatra et al. | Nov 2012 | A1 |
| 20120303019 | Zhao et al. | Nov 2012 | A1 |
| 20120310052 | Mahapatra et al. | Dec 2012 | A1 |
| 20120310230 | Willis | Dec 2012 | A1 |
| 20120310237 | Swanson | Dec 2012 | A1 |
| 20120316557 | Sartor et al. | Dec 2012 | A1 |
| 20130030430 | Stewart et al. | Jan 2013 | A1 |
| 20130060247 | Sklar et al. | Mar 2013 | A1 |
| 20130060248 | Sklar et al. | Mar 2013 | A1 |
| 20130079768 | De Luca et al. | Mar 2013 | A1 |
| 20130090651 | Smith | Apr 2013 | A1 |
| 20130096655 | Moffitt et al. | Apr 2013 | A1 |
| 20130103027 | Sklar et al. | Apr 2013 | A1 |
| 20130103064 | Arenson et al. | Apr 2013 | A1 |
| 20130131662 | Wittkampf | May 2013 | A1 |
| 20130158538 | Govari | Jun 2013 | A1 |
| 20130158621 | Ding et al. | Jun 2013 | A1 |
| 20130172715 | Just et al. | Jul 2013 | A1 |
| 20130172864 | Ibrahim et al. | Jul 2013 | A1 |
| 20130172875 | Govari et al. | Jul 2013 | A1 |
| 20130184702 | Neal, II et al. | Jul 2013 | A1 |
| 20130218157 | Callas et al. | Aug 2013 | A1 |
| 20130226174 | Ibrahim et al. | Aug 2013 | A1 |
| 20130237984 | Sklar | Sep 2013 | A1 |
| 20130253415 | Sano et al. | Sep 2013 | A1 |
| 20130274733 | Hancock | Oct 2013 | A1 |
| 20130296679 | Condie et al. | Nov 2013 | A1 |
| 20130310829 | Cohen | Nov 2013 | A1 |
| 20130317385 | Sklar et al. | Nov 2013 | A1 |
| 20130331831 | Werneth et al. | Dec 2013 | A1 |
| 20130338467 | Grasse et al. | Dec 2013 | A1 |
| 20140005664 | Govari et al. | Jan 2014 | A1 |
| 20140024911 | Harlev et al. | Jan 2014 | A1 |
| 20140039288 | Shih | Feb 2014 | A1 |
| 20140051993 | McGee | Feb 2014 | A1 |
| 20140052118 | Laske et al. | Feb 2014 | A1 |
| 20140052126 | Long et al. | Feb 2014 | A1 |
| 20140052216 | Long et al. | Feb 2014 | A1 |
| 20140058377 | Deem et al. | Feb 2014 | A1 |
| 20140081113 | Cohen et al. | Mar 2014 | A1 |
| 20140100563 | Govari et al. | Apr 2014 | A1 |
| 20140107644 | Falwell et al. | Apr 2014 | A1 |
| 20140142408 | De La Rama et al. | May 2014 | A1 |
| 20140148804 | Ward et al. | May 2014 | A1 |
| 20140163480 | Govari et al. | Jun 2014 | A1 |
| 20140163546 | Govari et al. | Jun 2014 | A1 |
| 20140171942 | Werneth et al. | Jun 2014 | A1 |
| 20140180035 | Anderson | Jun 2014 | A1 |
| 20140187916 | Clark et al. | Jul 2014 | A1 |
| 20140194716 | Diep et al. | Jul 2014 | A1 |
| 20140194864 | Martin | Jul 2014 | A1 |
| 20140194867 | Fish et al. | Jul 2014 | A1 |
| 20140200567 | Cox et al. | Jul 2014 | A1 |
| 20140235986 | Harlev et al. | Aug 2014 | A1 |
| 20140235988 | Ghosh | Aug 2014 | A1 |
| 20140235989 | Wodlinger et al. | Aug 2014 | A1 |
| 20140243851 | Cohen et al. | Aug 2014 | A1 |
| 20140276760 | Bonyak et al. | Sep 2014 | A1 |
| 20140276782 | Paskar | Sep 2014 | A1 |
| 20140276791 | Ku et al. | Sep 2014 | A1 |
| 20140288556 | Ibrahim et al. | Sep 2014 | A1 |
| 20140303721 | Fung et al. | Oct 2014 | A1 |
| 20140343549 | Spear et al. | Nov 2014 | A1 |
| 20140364845 | Rashidi | Dec 2014 | A1 |
| 20140371613 | Narayan et al. | Dec 2014 | A1 |
| 20150005767 | Werneth et al. | Jan 2015 | A1 |
| 20150011995 | Avitall et al. | Jan 2015 | A1 |
| 20150066108 | Shi et al. | Mar 2015 | A1 |
| 20150119674 | Fischell et al. | Apr 2015 | A1 |
| 20150126840 | Thakur et al. | May 2015 | A1 |
| 20150133914 | Koblish | May 2015 | A1 |
| 20150138977 | Dacosta | May 2015 | A1 |
| 20150141978 | Subramaniam et al. | May 2015 | A1 |
| 20150142041 | Kendale et al. | May 2015 | A1 |
| 20150148796 | Bencini | May 2015 | A1 |
| 20150150472 | Harlev et al. | Jun 2015 | A1 |
| 20150157402 | Kunis et al. | Jun 2015 | A1 |
| 20150157412 | Wallace et al. | Jun 2015 | A1 |
| 20150164584 | Davalos et al. | Jun 2015 | A1 |
| 20150173824 | Davalos et al. | Jun 2015 | A1 |
| 20150173828 | Avitall | Jun 2015 | A1 |
| 20150174404 | Rousso et al. | Jun 2015 | A1 |
| 20150182740 | Mickelsen | Jul 2015 | A1 |
| 20150196217 | Harlev et al. | Jul 2015 | A1 |
| 20150223726 | Harlev et al. | Aug 2015 | A1 |
| 20150230699 | Berul et al. | Aug 2015 | A1 |
| 20150258344 | Tandri et al. | Sep 2015 | A1 |
| 20150265342 | Long et al. | Sep 2015 | A1 |
| 20150265344 | Aktas et al. | Sep 2015 | A1 |
| 20150272656 | Chen | Oct 2015 | A1 |
| 20150272664 | Cohen | Oct 2015 | A9 |
| 20150272667 | Govari et al. | Oct 2015 | A1 |
| 20150282729 | Harlev et al. | Oct 2015 | A1 |
| 20150289923 | Davalos et al. | Oct 2015 | A1 |
| 20150304879 | Dacosta | Oct 2015 | A1 |
| 20150320481 | Cosman et al. | Nov 2015 | A1 |
| 20150321021 | Tandri et al. | Nov 2015 | A1 |
| 20150342532 | Basu et al. | Dec 2015 | A1 |
| 20150343212 | Rousso et al. | Dec 2015 | A1 |
| 20150351836 | Prutchi | Dec 2015 | A1 |
| 20150359583 | Swanson | Dec 2015 | A1 |
| 20160000500 | Salahieh et al. | Jan 2016 | A1 |
| 20160008061 | Fung et al. | Jan 2016 | A1 |
| 20160008065 | Gliner et al. | Jan 2016 | A1 |
| 20160029960 | Toth et al. | Feb 2016 | A1 |
| 20160038772 | Thapliyal et al. | Feb 2016 | A1 |
| 20160051204 | Harlev et al. | Feb 2016 | A1 |
| 20160051324 | Stewart et al. | Feb 2016 | A1 |
| 20160058493 | Neal, II et al. | Mar 2016 | A1 |
| 20160058506 | Spence et al. | Mar 2016 | A1 |
| 20160066993 | Avitall et al. | Mar 2016 | A1 |
| 20160074679 | Thapliyal et al. | Mar 2016 | A1 |
| 20160095531 | Narayan et al. | Apr 2016 | A1 |
| 20160095642 | Deno et al. | Apr 2016 | A1 |
| 20160095653 | Lambert et al. | Apr 2016 | A1 |
| 20160100797 | Mahapatra et al. | Apr 2016 | A1 |
| 20160100884 | Fay et al. | Apr 2016 | A1 |
| 20160106498 | Highsmith et al. | Apr 2016 | A1 |
| 20160106500 | Olson | Apr 2016 | A1 |
| 20160113709 | Maor | Apr 2016 | A1 |
| 20160113712 | Cheung et al. | Apr 2016 | A1 |
| 20160120564 | Kirkpatrick et al. | May 2016 | A1 |
| 20160128770 | Afonso et al. | May 2016 | A1 |
| 20160166167 | Narayan et al. | Jun 2016 | A1 |
| 20160166310 | Stewart et al. | Jun 2016 | A1 |
| 20160166311 | Long et al. | Jun 2016 | A1 |
| 20160174865 | Stewart et al. | Jun 2016 | A1 |
| 20160183877 | Williams et al. | Jun 2016 | A1 |
| 20160184003 | Srimathveeravalli et al. | Jun 2016 | A1 |
| 20160184004 | Hull et al. | Jun 2016 | A1 |
| 20160213282 | Leo et al. | Jul 2016 | A1 |
| 20160220307 | Miller et al. | Aug 2016 | A1 |
| 20160235470 | Callas et al. | Aug 2016 | A1 |
| 20160287314 | Arena et al. | Oct 2016 | A1 |
| 20160310211 | Long | Oct 2016 | A1 |
| 20160324564 | Gerlach et al. | Nov 2016 | A1 |
| 20160324573 | Mickelsen et al. | Nov 2016 | A1 |
| 20160331441 | Konings | Nov 2016 | A1 |
| 20160331459 | Townley et al. | Nov 2016 | A1 |
| 20160354142 | Pearson et al. | Dec 2016 | A1 |
| 20160361109 | Weaver et al. | Dec 2016 | A1 |
| 20170001016 | De Ridder | Jan 2017 | A1 |
| 20170035499 | Stewart et al. | Feb 2017 | A1 |
| 20170042449 | Deno et al. | Feb 2017 | A1 |
| 20170042615 | Salahieh et al. | Feb 2017 | A1 |
| 20170056648 | Syed et al. | Mar 2017 | A1 |
| 20170065330 | Mickelsen et al. | Mar 2017 | A1 |
| 20170065339 | Mickelsen | Mar 2017 | A1 |
| 20170065340 | Long | Mar 2017 | A1 |
| 20170065343 | Mickelsen | Mar 2017 | A1 |
| 20170071543 | Basu et al. | Mar 2017 | A1 |
| 20170095291 | Harrington et al. | Apr 2017 | A1 |
| 20170105793 | Cao et al. | Apr 2017 | A1 |
| 20170146584 | Daw et al. | May 2017 | A1 |
| 20170151029 | Mickelsen | Jun 2017 | A1 |
| 20170172654 | Wittkampf et al. | Jun 2017 | A1 |
| 20170181795 | Debruyne | Jun 2017 | A1 |
| 20170189097 | Viswanathan et al. | Jul 2017 | A1 |
| 20170215953 | Long et al. | Aug 2017 | A1 |
| 20170245928 | Xiao et al. | Aug 2017 | A1 |
| 20170246455 | Athos et al. | Aug 2017 | A1 |
| 20170312024 | Harlev et al. | Nov 2017 | A1 |
| 20170312025 | Harlev et al. | Nov 2017 | A1 |
| 20170312027 | Harlev et al. | Nov 2017 | A1 |
| 20180001056 | Leeflang et al. | Jan 2018 | A1 |
| 20180001085 | Cadossi | Jan 2018 | A1 |
| 20180042674 | Mickelsen | Feb 2018 | A1 |
| 20180042675 | Long | Feb 2018 | A1 |
| 20180043153 | Viswanathan et al. | Feb 2018 | A1 |
| 20180064488 | Long et al. | Mar 2018 | A1 |
| 20180085160 | Viswanathan et al. | Mar 2018 | A1 |
| 20180093088 | Mickelsen | Apr 2018 | A1 |
| 20180133460 | Townley et al. | May 2018 | A1 |
| 20180154142 | Guo | Jun 2018 | A1 |
| 20180168511 | Hall et al. | Jun 2018 | A1 |
| 20180184982 | Basu et al. | Jul 2018 | A1 |
| 20180193090 | de la Rama et al. | Jul 2018 | A1 |
| 20180200497 | Mickelsen | Jul 2018 | A1 |
| 20180303488 | Hill | Oct 2018 | A1 |
| 20180311497 | Viswanathan et al. | Nov 2018 | A1 |
| 20180344393 | Gruba et al. | Dec 2018 | A1 |
| 20180360534 | Teplitsky et al. | Dec 2018 | A1 |
| 20190069950 | Viswanathan et al. | Mar 2019 | A1 |
| 20190151015 | Viswanathan et al. | May 2019 | A1 |
| 20190183378 | Mosesov et al. | Jun 2019 | A1 |
| 20190231421 | Viswanathan et al. | Aug 2019 | A1 |
| 20190269912 | Viswanathan et al. | Sep 2019 | A1 |
| 20190336198 | Viswanathan et al. | Nov 2019 | A1 |
| 20190336207 | Viswanathan | Nov 2019 | A1 |
| 20200397498 | Mickelsen et al. | Dec 2020 | A1 |
| 20210031020 | Mickelsen | Feb 2021 | A1 |
| 20210052325 | Viswanathan et al. | Feb 2021 | A1 |
| 20210077188 | Long et al. | Mar 2021 | A1 |
| Number | Date | Country |
|---|---|---|
| 1042990 | Oct 2000 | EP |
| 1125549 | Aug 2001 | EP |
| 0797956 | Jun 2003 | EP |
| 1127552 | Jun 2006 | EP |
| 1340469 | Mar 2007 | EP |
| 1009303 | Jun 2009 | EP |
| 2213729 | Aug 2010 | EP |
| 2425871 | Mar 2012 | EP |
| 1803411 | Aug 2012 | EP |
| 2532320 | Dec 2012 | EP |
| 2587275 | May 2013 | EP |
| 2663227 | Nov 2013 | EP |
| 1909678 | Jan 2014 | EP |
| 2217165 | Mar 2014 | EP |
| 2376193 | Mar 2014 | EP |
| 2708181 | Mar 2014 | EP |
| 2777579 | Sep 2014 | EP |
| 2934307 | Oct 2015 | EP |
| 2777585 | Jun 2016 | EP |
| 2382935 | Mar 2018 | EP |
| 3111871 | Mar 2018 | EP |
| 3151773 | Apr 2018 | EP |
| 3056242 | Jul 2018 | EP |
| H06-507797 | Sep 1994 | JP |
| H10-510745 | Oct 1998 | JP |
| 2000-508196 | Jul 2000 | JP |
| 2005-516666 | Jun 2005 | JP |
| 2006-506184 | Feb 2006 | JP |
| 2007-325935 | Dec 2007 | JP |
| 2008-538997 | Nov 2008 | JP |
| 2009-500129 | Jan 2009 | JP |
| 2011-509158 | Mar 2011 | JP |
| 2012-050538 | Mar 2012 | JP |
| WO 9207622 | May 1992 | WO |
| WO 9221278 | Dec 1992 | WO |
| WO 9221285 | Dec 1992 | WO |
| WO 9407413 | Apr 1994 | WO |
| WO 9724073 | Jul 1997 | WO |
| WO 9725917 | Jul 1997 | WO |
| WO 9737719 | Oct 1997 | WO |
| WO 1999004851 | Feb 1999 | WO |
| WO 1999022659 | May 1999 | WO |
| WO 1999056650 | Nov 1999 | WO |
| WO 1999059486 | Nov 1999 | WO |
| WO 2002056782 | Jul 2002 | WO |
| WO 2003053289 | Jul 2003 | WO |
| WO 2003065916 | Aug 2003 | WO |
| WO 2004045442 | Jun 2004 | WO |
| WO 2004086994 | Oct 2004 | WO |
| WO 2005046487 | May 2005 | WO |
| WO 2006115902 | Nov 2006 | WO |
| WO 2007006055 | Jan 2007 | WO |
| WO 2007079438 | Jul 2007 | WO |
| WO 2009082710 | Jul 2009 | WO |
| WO 2009089343 | Jul 2009 | WO |
| WO 2009137800 | Nov 2009 | WO |
| WO 2010014480 | Feb 2010 | WO |
| WO 2011028310 | Mar 2011 | WO |
| WO 2011154805 | Dec 2011 | WO |
| WO 2012051433 | Apr 2012 | WO |
| WO 2012153928 | Nov 2012 | WO |
| WO 2013019385 | Feb 2013 | WO |
| WO 2014008489 | Jan 2014 | WO |
| WO 2014025394 | Feb 2014 | WO |
| WO 2014031800 | Feb 2014 | WO |
| WO 2014036439 | Mar 2014 | WO |
| WO 2014160832 | Oct 2014 | WO |
| WO 2015066322 | May 2015 | WO |
| WO 2015099786 | Jul 2015 | WO |
| WO 2015103530 | Jul 2015 | WO |
| WO 2015103574 | Jul 2015 | WO |
| WO 2015130824 | Sep 2015 | WO |
| WO 2015140741 | Sep 2015 | WO |
| WO 2015143327 | Sep 2015 | WO |
| WO 2015171921 | Nov 2015 | WO |
| WO 2015175944 | Nov 2015 | WO |
| WO 2015192018 | Dec 2015 | WO |
| WO 2015192027 | Dec 2015 | WO |
| WO 2016059027 | Apr 2016 | WO |
| WO 2016060983 | Apr 2016 | WO |
| WO 2016081650 | May 2016 | WO |
| WO 2016090175 | Jun 2016 | WO |
| WO 2017093926 | Jun 2017 | WO |
| WO 2017119934 | Jul 2017 | WO |
| WO 2017120169 | Jul 2017 | WO |
| WO 2017192477 | Nov 2017 | WO |
| WO 2017192495 | Nov 2017 | WO |
| WO 2017218734 | Dec 2017 | WO |
| WO 2018005511 | Jan 2018 | WO |
| WO 2018200800 | Nov 2018 | WO |
| WO 2019133606 | Jul 2019 | WO |
| Entry |
|---|
| Office Action for Canadian Application No. 2,881,462, dated Mar. 19, 2019, 5 pages. |
| Partial Supplementary European Search Report for European Application No. 13827672.0, mailed Mar. 23, 2016, 6 pages. |
| Supplementary European Search Report for European Application No. 13827672.0, mailed Jul. 11, 2016, 12 pages. |
| Office Action for European Application No. 13827672.0, mailed Feb. 5, 2018, 6 pages. |
| Notice of Reasons for Rejection for Japanese Application No. 2015-526522, mailed Mar. 6, 2017, 3 pages. |
| Office Action for U.S. Appl. No. 14/400,455, mailed Mar. 30, 2017, 10 pages. |
| International Search Report and Written Opinion for International Application No. PCT/US2013/031252, mailed Jul. 19, 2013, 12 pages. |
| Extended European Search Report for European Application No. 19182099.2, mailed Dec. 13, 2019, 7 pages. |
| Office Action for Japanese Application No. 2018-036714, dated Jan. 16, 2019, 8 pages. |
| Office Action for Japanese Application No. 2018-036714, dated Nov. 27, 2019, 5 pages. |
| Office Action for U.S. Appl. No. 15/819,726, mailed Jun. 4, 2018, 17 pages. |
| Office Action for U.S. Appl. No. 15/917,194, mailed Jun. 4, 2018, 17 pages. |
| Office Action for U.S. Appl. No. 15/917,194, mailed Oct. 9, 2018, 13 pages. |
| Office Action for U.S. Appl. No. 15/917,194, mailed Apr. 29, 2019, 10 pages. |
| Office Action for U.S. Appl. No. 15/917,194, mailed Dec. 20, 2019, 10 pages. |
| First Office Action for Chinese Application No. 201580006848.8, dated Jan. 29, 2018, 15 pages. |
| Office Action for European Application No. 15701856.5, mailed Dec. 11, 2017, 6 pages. |
| Notice of Reasons for Rejection for Japanese Application No. 2016-544072, mailed Oct. 1, 2018, 11 pages. |
| Office Action for U.S. Appl. No. 15/201,983, mailed Apr. 3, 2019, 16 pages. |
| Office Action for U.S. Appl. No. 15/201,983, mailed Nov. 15, 2019, 15 pages. |
| International Search Report and Written Opinion for International Application No. PCT/US2015/010138, mailed Mar. 26, 2015, 14 pages. |
| International Preliminary Report on Patentability for International Application No. PCT/US2015/010138, dated Jul. 12, 2016, 9 pages. |
| Supplementary European Search Report for European Application No. 15733297.4, mailed Aug. 10, 2017, 7 pages. |
| Office Action for U.S. Appl. No. 15/201,997, mailed Apr. 3, 2017, 6 pages. |
| Office Action for U.S. Appl. No. 15/201,997, mailed Aug. 29, 2017, 12 pages. |
| Office Action for U.S. Appl. No. 15/201,997, mailed Jul. 12, 2018, 12 pages. |
| Office Action for U.S. Appl. No. 15/201,997, mailed Dec. 17, 2018, 17 pages. |
| International Search Report and Written Opinion for International Application No. PCT/US2015/010223, mailed Apr. 10, 2015, 19 pages. |
| International Preliminary Report on Patentability for International Application No. PCT/US2015/010223, dated Jul. 12, 2016, 12 pages. |
| Office Action for U.S. Appl. No. 15/341,512, mailed Aug. 1, 2019, 19 pages. |
| Office Action for U.S. Appl. No. 15/341,512, mailed Nov. 12, 2019, 18 pages. |
| International Search Report and Written Opinion for International Application No. PCT/US2015/029734, mailed Nov. 24, 2015, 15 pages. |
| Extended European Search Report for European Application No. 18189811.5, mailed May 14, 2019, 7 pages. |
| Office Action for U.S. Appl. No. 15/795,062, mailed Dec. 19, 2017, 14 pages. |
| Office Action for U.S. Appl. No. 15/795,062, mailed Apr. 9, 2018, 20 pages. |
| Office Action for U.S. Appl. No. 15/795,062, mailed May 3, 2019, 21 pages. |
| Office Action for U.S. Appl. No. 15/795,062, mailed Nov. 4, 2019, 23 pages. |
| Office Action for U.S. Appl. No. 15/341,523, mailed Jan. 29, 2019, 10 pages. |
| Office Action for U.S. Appl. No. 15/341,523, mailed Jul. 30, 2019, 8 pages. |
| International Search Report and Written Opinion for International Application No. PCT/US2015/031086, mailed Oct. 21, 2015, 16 pages. |
| Office Action for U.S. Appl. No. 15/795,075, mailed Feb. 6, 2018, 9 pages. |
| Office Action for U.S. Appl. No. 15/795,075, mailed Jun. 15, 2018, 10 pages. |
| Office Action for U.S. Appl. No. 15/795,075, mailed Apr. 10, 2019, 11 pages. |
| Office Action for U.S. Appl. No. 15/795,075, mailed Jul. 31, 2019, 12 pages. |
| Extended European Search Report for European Application No. 15849844.4, mailed May 3, 2018, 8 pages. |
| Office Action for U.S. Appl. No. 15/484,969, mailed Sep. 4, 2019, 12 pages. |
| Office Action for U.S. Appl. No. 15/484,969, mailed Jul. 16, 2020, 12 pages. |
| International Search Report and Written Opinion for International Application No. PCT/US2015/055105, mailed Mar. 1, 2016, 15 pages. |
| Office Action for U.S. Appl. No. 15/796,255, mailed Jan. 10, 2018, 12 pages. |
| Extended European Search Report for European Application No. 15806855.1, mailed Jan. 3, 2018, 8 pages. |
| Office Action for U.S. Appl. No. 15/354,475, mailed May 23, 2019, 7 pages. |
| International Search Report and Written Opinion for International Application No. PCT/US2015/035582, mailed Oct. 2, 2015, 17 pages. |
| Extended European Search Report for European Application No. 15806278.6, mailed Feb. 9, 2018, 5 pages. |
| International Search Report and Written Opinion for International Application No. PCT/US2015/035592, mailed Oct. 2, 2015, 13 pages. |
| Extended European Search Report for European Application No. 16884132.8, mailed Jul. 8, 2019, 7 pages. |
| Office Action for U.S. Appl. No. 15/334,646, mailed Jul. 25, 2017, 19 pages. |
| Office Action for U.S. Appl. No. 15/334,646, mailed Nov. 16, 2017, 26 pages. |
| International Search Report and Written Opinion for International Application No. PCT/US2016/057664, mailed Feb. 24, 2017, 11 pages. |
| Office Action for U.S. Appl. No. 15/796,375, mailed Jan. 24, 2018, 25 pages. |
| Office Action for U.S. Appl. No. 15/796,375, mailed May 30, 2018, 26 pages. |
| Office Action for U.S. Appl. No. 15/796,375, mailed Nov. 16, 2018, 27 pages. |
| Office Action for U.S. Appl. No. 16/416,677, mailed Aug. 15, 2019, 8 pages. |
| Extended European Search Report for European Application No. 17736218.3 mailed Aug. 23, 2019, 9 pages. |
| International Search Report and Written Opinion for International Application No. PCT/US2017/012099, mailed May 18, 2017, 17 pages. |
| Office Action for U.S. Appl. No. 15/711,266, mailed Feb. 23, 2018, 14 pages. |
| International Search Report and Written Opinion for International Application No. PCT/US2018/029938, mailed Aug. 29, 2018, 14 pages. |
| Office Action for U.S. Appl. No. 16/181,027, mailed Sep. 4, 2019, 12 pages. |
| International Search Report and Written Opinion for International Application No. PCT/US2019/014226, mailed Apr. 29, 2019, 15 pages. |
| Office Action for U.S. Appl. No. 16/240,066, mailed May 29, 2019, 7 pages. |
| Office Action for U.S. Appl. No. 16/375,561, mailed Oct. 17, 2019, 15 pages. |
| International Search Report and Written Opinion for International Application No. PCT/US2017/037609, mailed Nov. 8, 2017, 13 pages. |
| Office Action for U.S. Appl. No. 15/672,916, mailed Feb. 13, 2018, 16 pages. |
| Office Action for U.S. Appl. No. 15/672,916, mailed Jul. 20, 2018, 23 pages. |
| Office Action for U.S. Appl. No. 15/672,916, mailed Apr. 9, 2019, 31 pages. |
| Office Action for U.S. Appl. No. 15/499,804, mailed Jan. 3, 2018, 20 pages. |
| Office Action for U.S. Appl. No. 15/794,717, mailed Feb. 1, 2018, 10 pages. |
| International Search Report and Written Opinion for International Application No. PCT/US2018/029552, mailed Jun. 29, 2018, 13 pages. |
| Partial European Search Report for European Application No. 18170210.1, mailed Feb. 14, 2019, 13 pages. |
| Extended European Search Report for European Application No. 18170210.1, mailed May 17, 2019, 11 pages. |
| International Search Report and Written Opinion for International Application No. PCT/US2018/050660, mailed Nov. 26, 2018, 13 pages. |
| Office Action for U.S. Appl. No. 15/970,404, mailed Oct. 9, 2018, 21 pages. |
| Office Action for U.S. Appl. No. 15/970,404, mailed Apr. 12, 2019, 20 pages. |
| Office Action for U.S. Appl. No. 15/970,404, mailed Nov. 12, 2019, 19 pages. |
| International Search Report and Written Opinion for International Application No. PCT/US2019/028943, mailed Sep. 17, 2019, 17 pages. |
| International Search Report and Written Opinion for International Application No. PCT/US2019/017322, mailed May 10, 2019, 15 pages. |
| International Search Report and Written Opinion for International Application No. PCT/US2019/030922, mailed Sep. 6, 2019, 12 pages. |
| International Search Report and Written Opinion for International Application No. PCT/US2019/030882, mailed Sep. 10, 2019, 17 pages. |
| Office Action for U.S. Appl. No. 16/573,704, mailed Dec. 17, 2019, 6 pages. |
| Office Action for U.S. Appl. No. 16/405,515, mailed Sep. 6, 2019, 9 pages. |
| International Search Report and Written Opinion for International Application No. PCT/US2019/031135, mailed Aug. 5, 2019, 11 pages. |
| Du Pre, B.C. et al., “Minimal coronary artery damage by myocardial electroporation ablation,” Europace, 15(1):144-149 (2013). |
| Hobbs, E. P., “Investor Relations Update: Tissue Ablation via Irreversible Electroporation (IRE),” Powerpoint (2004), 16 pages. |
| Lavee, J. et al., “A Novel Nonthermal Energy Source for Surgical Epicardial Atrial Ablation: Irreversible Electroporation,” The Heart Surgery Forum #2006-1202, 10(2), 2007 [Epub Mar. 2007]. |
| Madhavan, M. et al., “Novel Percutaneous Epicardial Autonomic Modulation in the Canine for Atrial Fibrillation: Results of an Efficacy and Safety Study,” Pace, 00:1-11 (2016). |
| Neven, K. et al., “Safety and Feasibility of Closed Chest Epicardial Catheter Ablation Using Electroporation,” Circ Arrhythm Electrophysiol., 7:913-919 (2014). |
| Neven, K. et al., “Myocardial Lesion Size After Epicardial Electroporation Catheter Ablation After Subxiphoid Puncture,” Circ Arrhythm Electrophysiol., 7(4):728-733 (2014). |
| Neven, K. et al., “Epicardial linear electroporation ablation and lesion size,” Heart Rhythm, 11:1465-1470 (2014). |
| Van Driel, V.J.H.M. et al., “Pulmonary Vein Stenosis After Catheter Ablation Electroporation Versus Radiofrequency,” Circ Arrhythm Electrophysiol., 7(4):734-738 (2014). |
| Van Driel, V.J.H.M. et al., “Low vulnerability of the right phrenic nerve to electroporation ablation,” Heart Rhythm, 12:1838-1844 (2015). |
| Wittkampf, F.H. et al., “Myocardial Lesion Depth With Circular Electroporation Ablation,” Circ. Arrhythm Electrophysiol., 5(3):581-586 (2012). |
| Wittkampf, F.H. et al., “Feasibility of Electroporation for the Creation of Pulmonary Vein Ostial Lesions,” J Cardiovasc Electrophysiol, 22(3):302-309 (Mar. 2011). |
| Office Action for European Application No. 15806855.1, mailed Jun. 4, 2021, 7 pages. |
| Number | Date | Country | |
|---|---|---|---|
| 20210045798 A1 | Feb 2021 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | PCT/US2019/028943 | Apr 2019 | WO |
| Child | 17087433 | US | |
| Parent | 15970404 | May 2018 | US |
| Child | PCT/US2019/028943 | US |
